

424 Rec'd PCT/PTO 16 FEB 2000

FORM PTO-1390 DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV 5-93)		ATTORNEY'S DOCKET NO. 790076.401
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>09 / 4 85 879</b>
		Unknown
INTERNATIONAL APPLICATION NO. <b>PCT/EP98/05360</b>	INTERNATIONAL FILING DATE <b>24 August 1998 (24.08.1998)</b>	PRIORITY DATE CLAIMED <b>22 August 1997 (22.08.97)</b>
TITLE OF INVENTION <b>METHOD FOR CHARACTERIZING DISSEMINATED AND MICROMETASTASIZED CANCER CELLS</b>		
APPLICANT(S) FOR DO/EO/US <b>giesing, Michael; AUSTRUP, Frank; DRIESEL, Gerhard; EDER, Claudine; FEIFEL, Nico; HOLEWA, Beatrix; SUCHY, Bernhard; and UCIECHOWSKI, Peter</b>		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> <li><input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li><input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li><input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li> <li><input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</li> <li><input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> <li><input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International bureau).</li> <li><input checked="" type="checkbox"/> has been transmitted by the International Bureau.</li> <li><input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li><input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</li> <li><input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). <ol style="list-style-type: none"> <li><input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li><input type="checkbox"/> have been transmitted by the International Bureau.</li> <li><input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li><input checked="" type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li><input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li><input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li><input checked="" type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>		
<b>Items 11 to 16 below concern document(s) or information included:</b> <ol style="list-style-type: none"> <li><input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li><input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li><input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</li> <li><input type="checkbox"/> A substitute specification.</li> <li><input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li><input checked="" type="checkbox"/> Other items or information: Postcard and check for filing fees. Applicant hereby claims priority from <b>German</b> Application No. <b>197 36 691.0</b> filed <b>22 August 1997</b>.</li> </ol>		

## EXPRESS MAIL MAILING LABEL

NUMBER EL487802105US

DATE OF DEPOSIT 16 February 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Assistant Commissioner for Patents, Washington D.C. 20231-0001

Signature

Table 1. Continued							
Age (years)	18-24	25-34	35-44	45-54	55-64	65-74	75+
Gender	Male	Female	Male	Female	Male	Female	Male
Marital status	Married	Single	Married	Single	Married	Single	Married
Education	High school or less	Some college	Bachelor's	Master's	PhD	Other	Other
Occupation	Unemployed	Service	Production	Professional	Managerial	Executive	Other
Income	<\$10,000	\$10,000-\$19,999	\$20,000-\$29,999	\$30,000-\$39,999	\$40,000-\$49,999	\$50,000-\$59,999	\$60,000+
Health insurance	Medicaid	Medicare	Private	Other	None	Other	Other
Chronic conditions	None	1	2	3	4	5	6+
Medication use	None	1	2	3	4	5	6+
Alcohol use	None	1	2	3	4	5	6+
Tobacco use	None	1	2	3	4	5	6+
Stress level	Low	Medium	High	Very high	Extremely high	Other	Other
Physical activity	Sedentary	Light	Medium	High	Very high	Extremely high	Other
Sleep quality	Good	Fair	Poor	Very poor	Extremely poor	Other	Other
Mental health	Good	Fair	Poor	Very poor	Extremely poor	Other	Other
Social support	Strong	Medium	Weak	Very weak	Extremely weak	Other	Other
Healthcare access	Good	Fair	Poor	Very poor	Extremely poor	Other	Other
Healthcare utilization	Low	Medium	High	Very high	Extremely high	Other	Other
Healthcare satisfaction	High	Medium	Low	Very low	Extremely low	Other	Other
Healthcare access barriers	None	1	2	3	4	5	6+
Healthcare utilization barriers	None	1	2	3	4	5	6+
Healthcare satisfaction barriers	None	1	2	3	4	5	6+
Healthcare access facilitators	None	1	2	3	4	5	6+
Healthcare utilization facilitators	None	1	2	3	4	5	6+
Healthcare satisfaction facilitators	None	1	2	3	4	5	6+
Healthcare access barriers	None	1	2	3	4	5	6+
Healthcare utilization barriers	None	1	2	3	4	5	6+
Healthcare satisfaction barriers	None	1	2	3	4	5	6+
Healthcare access facilitators	None	1	2	3	4	5	6+
Healthcare utilization facilitators	None	1	2	3	4	5	6+
Healthcare satisfaction facilitators	None	1	2	3	4	5	6+
Healthcare access barriers	None	1	2	3	4	5	6+
Healthcare utilization barriers	None	1	2	3	4	5	6+
Healthcare satisfaction barriers	None	1	2	3	4	5	6+
Healthcare access facilitators	None	1	2	3	4	5	6+
Healthcare utilization facilitators	None	1	2	3	4	5	6+
Healthcare satisfaction facilitators	None	1	2	3	4	5	6+
Healthcare access barriers	None	1	2	3	4	5	6+
Healthcare utilization barriers	None	1	2	3	4	5	6+
Healthcare satisfaction barriers	None	1	2	3	4	5	6+
Healthcare access facilitators	None	1	2	3	4	5	6+
Healthcare utilization facilitators	None	1	2	3	4	5	6+
Healthcare satisfaction facilitators	None	1	2	3	4	5	6+
Healthcare access barriers	None	1	2	3	4	5	6+
Healthcare utilization barriers	None	1	2	3	4	5	6+
Healthcare satisfaction barriers	None	1	2	3	4	5	6+
Healthcare access facilitators	None	1	2	3	4	5	6+
Healthcare utilization facilitators	None	1	2	3	4	5	6+
Healthcare satisfaction facilitators	None	1	2	3	4	5	6+
Healthcare access barriers	None	1	2	3	4	5	6+
Healthcare utilization barriers	None	1	2	3	4	5	6+
Healthcare satisfaction barriers	None	1	2	3	4	5	6+
Healthcare access facilitators	None	1	2	3	4	5	6+
Healthcare utilization facilitators	None	1	2	3	4	5	6+
Healthcare satisfaction facilitators	None	1	2	3	4	5	6+
Healthcare access barriers	None	1	2	3	4	5	6+
Healthcare utilization barriers	None	1	2	3	4	5	6+
Healthcare satisfaction barriers	None	1	2	3	4	5	6+
Healthcare access facilitators	None	1	2	3	4	5	6+
Healthcare utilization facilitators	None	1	2	3</			

\\MAIN\USERS\ERICG\CLIENT\_FILES\_US\790076\401\US\_PCT\_CONVERSION\_TRANSMITTAL\_LTR\_2B.DOC)

416 Rec'd PCT/PTO 16 FEB 2000

METHOD FOR THE CHARACTERIZATION OF DISSEMINATED AND  
MICROMETASTASIZED CANCER CELLS

5  
10 The present invention relates to a method for the characterization of disseminated and micrometastasized cancer cells on the basis of RNA and/or DNA, to the use of this method for in vitro diagnosis of cancer and the use of cancer cells characterized according to the invention for testing active substances for an anti-neoplastic effect, and to means for carrying out the method.

15 The diagnosis of cancer in humans continues to represent one of the greatest challenges to present-day medicine. It is frequently possible with current diagnostic methods to identify cancerous growths, which are embraced  
20 hereinafter by the term tumours (sarcomas, carcinomas, systemic haematological malignancies), only when the tumour has already reached an advanced stage. Despite considerable advances in imaging methods, a certain minimum size of the tumour is always necessary for  
25 successful use thereof. In addition, only very little, if any, further information about the nature and constitution of the tumour can be obtained with such methods. The time-consuming and cost-intensive imaging methods are therefore usually employed merely as aids to  
30 orientation for the subsequent, frequently direct, procedure, usually removal of tissue. However, this means an invasive procedure on the patient's body which may, depending on the location and constitution of the tumour, be very unpleasant or even dangerous for the patient.

35 If a tumour is diagnosed on the basis of such a tissue removal, it is normal for further investigations to

09485879.062200

follow with the intention of, for example, describing the potential for spread, that is to say the formation of metastases, by this tumour. If, for example, breast cancer is diagnosed, it is usual to remove 20 to 30 lymph nodes from the patient involved and determine the number of lymph nodes having cancer cells. The prevailing opinion is that the patient's chances of survival decrease with an increasing number of lymph nodes affected. However, recent findings indicate that the occurrence of such lymph node metastases is a measure more of the age than of the aggressiveness or the metastasis potential of the tumour.

New ways of diagnosing cancer have appeared in recent years during the progressive development of methods of molecular biology and the increasing knowledge about the genetic bases of cellular degeneration. It has been assumed that cancer cells express characteristic markers, on the basis of which they ought to be distinguishable from nondegenerate cells and thus identifiable as cancer cells. The development of the hybridoma technique and the cultivation of monoclonal antibodies made possible thereby has led to the design of a large number of immunoassays intended to contribute to the diagnosis of cancer by detecting particular markers. Examples of such markers are carcinoembryonic antigen (CEA),  $\alpha$ -fetoprotein (AFP) or prostate-specific antigen (PSA). EP 0 747 705 has recently proposed investigation only of the 90 kDa glycoform of a group of proteins (NCAs) structurally related to CEA in the blood because apparently only this glycoform is released into the bloodstream. WO 96/21862 indicates that measurement of the concentration of A-protein in the blood would allow diagnosis of cancer, but also states that the hopes placed on the markers investigated hitherto, such as CEA, AFP or PSA, have not been fulfilled. Other methods based on the immunological

detection of particular proteins are described, for example, in DE 195 00 723; WO 97/26271; WO 97/28186; WO 96/01907; US 5,633,142; US 5,620,848; US 5,589,579; and US 5,563,247. However, a reliable diagnosis of cancer  
5 does not appear to be possible in this way at least at present.

Other research teams have, by contrast, concentrated on analysing the genetic material of cancer cells. Thus,  
10 WO 93/04200 proposes, for estimating a predisposition to breast cancer, isolating DNA from a sample of the patient's blood, restricting this DNA in a particular way and making an appropriate diagnosis on the basis of the restriction pattern. However, a detection of tumour cells  
15 in the blood is not possible with this method.

Furthermore, WO 96/02671 describes a method with which genomic DNA or cDNA from neoplastic tissue, blood or another body fluid is investigated, solely by sequence  
20 analysis (sequencing or hybridization), for mutations of a gene which codes for a protein whose disturbed function is thought to be connected with cancer. Similar approaches are reported in WO 97/26271; WO 97/28186; WO 96/15262; WO 96/01907; WO 93/22456; US 5,620,848;  
25 US 5,149,628 and WO 96/21021.

There have also been many proposals to investigate the free DNA and/or RNA present in blood plasma for oncogenic mutations or deletions, tumour suppressor gene mutations  
30 or deletions or changes in the microsatellite pattern (compare, for example, WO 95/16792; DE 37 21 400; DE 37 17 212; and WO 93/22456).

Finally, WO 94/10343 also describes a method for  
35 diagnosing cancer, namely for identifying prostate cancer micrometastases, entailing investigation of a patient's

002230" 6/853460

blood for RNA coding for prostate-specific antigen. However, so-called false-positive responses are obtained in about two thirds of the cases with this method, because inflammations of or injuries to the prostate gland also increase the concentration of the protein in the blood. On the other hand, because of inadequacies in the test, presumably 30% of cancers still remain undiscovered. A similar procedure is chosen in US 5,601,990 for diagnosing metastasizing bowel cancer.

In summary, therefore, it can be stated that the prior art provides no reliable diagnosis of cancer.

The present invention is therefore based on the object of designing an in vitro method with which all types of cancer in mammals and, in particular, in humans can be identified and assessed reliably and with sufficient accuracy, also for individual patients, and which makes it possible to follow the progress of a suitable cancer therapy. The method is additionally intended to make it possible to test active substances for an antineoplastic effect.

This object is achieved according to the invention by a method for the characterization of disseminated and micrometastasized cancer cells on the basis of DNA and/or RNA, wherein cells obtained from body fluid from an individual are investigated for at least one cancer-specific gene on the basis of mRNA; and/or cancer cells removed from body fluid from an individual are investigated for at least one cancer-specific gene on the basis of DNA and/or mRNA, and the same investigation is carried out with non-cancer cells from the same individual for comparison.

Characterization means according to the invention all

procedures which can be carried out on cells from mammals and, in particular, from humans in order to detect qualitatively or quantitatively one, two, three, four, five, 6 to 10, 11 to 20 or more cancer-specific and/or cancer-associated genes in these cells. It is then possible to identify the cells on the basis of the results obtained in the characterization. This embraces according to the invention not only the qualitative detection of circulating cancer cells but may also comprise quantitation thereof and/or information about their origin and behaviour, for example in relation to metastasis formation or for a wide variety of, for example, cytotoxic, therapeutic approaches.

Circulating cancer cells include, according to the invention in particular those cancer cells which have become detached from the primary tumour, that is to say disseminated and micrometastasized cancer cells. For the purpose of simplification, reference will be made hereinafter to circulating cancer cells. Because the spread of these cells is usually connected with the vascularization of the primary tumour, circulating cancer cells can be found in particular in the blood, with bone marrow and lymph nodes also being suitable. Accordingly, body fluids such as blood, lymph, urine, bone marrow and various organ irrigation fluids such as bronchial lavage, pancreatic or bladder irrigation fluid are investigated according to the invention.

A distinction is made according to the invention between cancer-specific and cancer-associated genes. Cancer-specific in the sense according to the invention are those genes on the basis of which it is possible to identify a circulating cancer cell as such. Cancer-associated genes, by contrast, are not specific for cancer cells. They may also be expressed in healthy cells

or in a wide variety of other disorders, for example inflammations. However, expression thereof may be characteristically modulated in cancer cells in comparison with non-cancer cells, so that further  
5 conclusions can be drawn about the nature and the behaviour of the cancer cells.

In this sense, it is also possible, of course, that a particular gene may contribute to both the cancer-specific and the cancer-associated characterization. For  
10 example, a gene may have a mutation which leads to anomalous expression of a cell cycle-regulating protein and, as a consequence, to degeneration of the affected cell. This mutated gene is therefore cancer-specific and  
15 the investigation according to the invention for detecting this mutated gene serves for cancer-specific characterization. In addition, analysis of the anomalous expression of this gene may also contribute to the cancer-associated characterization because the nature or  
20 quantity of corresponding expression products are important for the cell cycle and thus further conclusions can be drawn about the nature and the behaviour of the cancer cells.

25 The investigation for cancer-specific and cancer-associated genes can be carried out in every way conceivable to the skilled person. Thus, a gene according to the invention can be investigated at the DNA level, at the RNA level and/or at the protein level. Investigation  
30 at the DNA level is preferably of genomic DNA for mutations, amplifications, LOHs, translocations and/or polymorphisms. Investigation at the RNA level and at the protein level is of expression products, namely and preferably transcription products such as mRNA and  
35 translation products such as proteins. Preferred methods are those able to assist in assessment of the involvement

002290 6289460



of a gene in the condition of circulating cells at the time of investigation, for example investigation of mRNA in particular in relation to the amount of a particular mRNA present in a cell. If the method according to the invention includes investigation of a body fluid for proteins, these are, in particular, ones expressed by the cancer-specific and/or cancer-associated genes. Unless indicated otherwise, references made hereinafter will embrace investigation or analysis of the genes according to the invention.

The specific genes mentioned in the following description are frequently referred to by abbreviations or codes which are customarily used and are therefore known to the skilled person. In addition, reference may be made to the glossary inserted at the end of the present description for explanation.

The cancer-specific genes according to the invention include, in particular, two classes of genes which play an essential part in the development of cancer: oncogenes which are produced by mutation from so-called proto-oncogenes, and mutated tumour suppressor genes. In their normal form, both direct the life cycle of a cell: proto-oncogenes promote cell growth, while tumour suppressor genes retard it. Oncogenes are cancer-favouring because they stimulate the cell to excessive proliferation, whereas tumour suppressor genes contribute to the development of cancer if they are inactivated by mutation and, as a consequence, the cell loses an inhibitor of growth by which inappropriate proliferation of it is normally prevented. Oncogenes code for example for growth factors and their receptors, signal proteins, transcription factors and a large number of other proteins, of which some, for example, play an important part in apoptosis. Oncogenes include, for example, genes

09485879.062200

such as the bcl-2 family, mdm2, c-abl, the myc family, for example c-, N-, R-, L- and B-myc, the ras family, for example H-, K- and N-ras, erb-B2, which is also called neu, erb-B, PDGF, RET and viral oncogenes of various  
5 tumour viruses such as papovaviruses, for example SV40, polyoma- and papillomaviruses such as HPV, adenoviruses, certain herpesviruses, poxviruses, hepatitis B viruses (HBx gene), hepatitis C viruses, HTLV-1, E1A fusion transcript in adenoviruses, E6 and E7 fusion transcripts  
10 in HPV and EBV in Burkitt's lymphoma.

Oncogenes preferred according to the invention are genes of the ras family, erb-B2, erb-B, c-myc, mdm2, bcl-2, hepatitis B viruses (HBx gene), hepatitis C viruses,  
15 HTLV1, E1A fusion transcript in adenoviruses, E6 and E7 fusion transcripts in HPV and EBV in Burkitt's lymphoma. Very particular preference is given to c-myc, k-ras and erb-B2.

20 The tumour suppressor genes include, for example, the genes of the APC family (FAP), DCC, DPC4, NF-1, NF-2, MTS1, RB, p53, WT1, BRCA1, BRCA2, VHL, MSH2, MLH1 and WAF1.

25 Tumour suppressor genes preferred according to the invention are p53, RB, APC, DCC, BRCA1, BRCA2, MSH2, MLH1 and WAF1. Very particular preference is given to p53, RB, APC, DCC and DPC4.

30 The cancer-specific genes include not only oncogenes and mutated tumour suppressor genes but also genes which are switched off, that is to say are expressed in only inconsiderable amounts, if at all, in non-cancer cells in body fluids investigated according to the invention. If,  
35 therefore, transcription and/or translation products of these genes are detected in a body fluid, for example

002290 62858460

blood, this indicates the presence of circulating cancer cells in the relevant body fluid.

These include, for example, hCG, hTG, calcitonin, albumin, surfactant proteins, telomerase, various translocations, Stat5a, variants of steroid receptors (ER, AR), progesterone receptor, various genes showing an LOH, CEA, PSM, PSA, AFP, tyrosinase, MAGE3, Muc18, MUC1, cytokeratins, in particular CK20 and CK19, LOH investigations in various chromosome sections by numerous microsatellites, gastrointestinal tract hormones such as motilin, enteroglucagon, GIP, gastrin, CCK or PYY, and neurotensin. Preference is given according to the invention to CEA, PSM, MUC1 (tumour-specific splice variants), AFP, cytokeratin, tyrosinase, MAGE3, MUC18, tumour-specific splice variants of the oestrogen and androgen receptors, and EGP.

Genes of this type also include the tissue-specific genes which are mentioned below and which, because of their tissue specificity, contribute to the cancer-associated characterization according to the invention, but can also be used, due to the specific nature of the object investigated, namely cancer cells detached from the primary tumour and circulating in a body fluid, for the cancer-specific characterization.

It is also possible to use prognostic oncoproteins, such as anti-p53, pan p53, p53 or c-erb-B2, for the cancer-specific investigation.

In a preferred embodiment of the present invention, a body fluid is investigated for at least one cancer-specific gene and at least one cancer-associated gene. For this purpose, cells obtained from body fluid from an individual are additionally investigated for at least one

002299-628460

cancer-associated gene which is essentially not expressed in non-cancer cells in the body fluid investigated; and/or cancer cells removed from body fluid from an individual are additionally investigated for at least one  
5 cancer-associated gene and the same investigation is carried out on non-cancer cells from the same individual for comparison.

002299.062200 09485879.062200  
10 The cancer-associated genes according to the invention embrace a wide range of functions. Particularly suitable ones are tissue-specific, that is to say organotypical, genes (morphogenes) which provide information on the origin of the circulating cancer cells, so that conclusions can be drawn about the location of the  
15 primary tumour, the source of spread; genes which characterize the ability of the cancer cells to metastasize; genes which code for steroid hormone receptors, so that information can be obtained about the receptor status of the cancer cells; drug resistance  
20 genes; or genes whose expression correlates with the modulation of the immune response, and cell proliferation and apoptosis of circulating cancer cells. Expression of these cancer-associated genes may be modulated in a characteristic way in cancer cells, so that the resulting  
25 expression pattern may also point to cancer.

Cancer-associated tissue-specific genes frequently code for organotypical markers, that is to say proteins or antigens, on the basis of which conclusions can be drawn  
30 about the origin of the cell expressing the gene. These include, for example, liver-specific genes such as albumin or AFP; prostate-specific such as AR, PSM, hK2 or PSA; breast-, ovary- and/or cervix-specific, such as B-hCG, ER, PR, SCCA-1, maspin or BA46; colorectal-  
35 specific such as CCK, enteroglucagon, GIP, gastrin, motilin or PYY; pancreas-specific such as PYY; melanoma-

specific such as MAGE1, MAGE3, Muc18 or tyrosinase; thyroid-specific such as hTG; lung-specific such as SF, SF-R, surfactant proteins, for example SP-A and SP-C, CC10, N-CoR or RAR $\beta$ 2; bladder-specific such as EGF-R and  $\beta$ -hCG; endometrium-specific such as SCCA.

It is also possible to have recourse to oncogenes and/or mutated tumour suppressor genes for the tissue-specific characterization if they point to particular types of cancer. Examples thereof are tumour-associated mutations such as translocation 14;18 (bcl-2) for lymphomas, translocation 9;22 (BCR/ABL) for chronic myeloid leukaemias, translocation 15;17 for acute non-lymphocytic leukaemias, translocation 2;13 (PAX3-FKHR) and translocation 1;13 (PAX7-FKHR) for alveolar rhabdomyosarcomas, translocation 11;22 for Ewing's sarcomas, translocation 12;16 for myxoid liposarcomas, translocation x;18 for synovial sarcomas; BRCA-1 and BRCA-2 for breast carcinomas, DPC-4 for pancreatic carcinomas, erb-B for glioblastomas, MLH-1 and MSH-2 for HNPCC (hereditary nonpolyposis colon cancer), NF-2 for neurofibromatosis-1, NF-1 for neurofibromatosis, RET for thyroid carcinomas, RB for retinoblastomas, VHL for renal carcinomas, WT-1 for renal tumours, and k-ras for colon carcinomas.

Characterization of the ability of circulating cancer cells to metastasize occupies a special position according to the invention. For this purpose, the cells are investigated in particular for genes which code for angiogenesis, growth and motility factors, matrix degradation factors such as proteases and their inhibitors, or adhesion factors such as adherins.

Angiogenesis factors include, for example, aFGF and bFGF and their receptors aFGF-R and bFGF-R, VEGF and its

receptors VEGF-R1 and VEGF-R2, and GD-AIF.

Growth factors include, for example, TGF- $\alpha$  and TGF- $\beta$ , IGF, IGF-BP3, erb-B (EGF-R), PDGF and EGF.

5

The migration-stimulating motility factors include, for example, the scatter factor SF-L and its receptor SF-R (c-met).

- 10 Proteases and their inhibitors embrace, for example, matrix hydrolases such as MMPs (matrix metalloproteases), MT-MMP, UPA (urokinase-like plasminogen activator) or inhibitors thereof such as PAI1 and PAI2 (plasminogen activator inhibitor) or TIMPs (tissue inhibitors of
- 15 metalloproteases).

- The adherins include adhesion proteins such as cadherins, for example E-cadherin, catenins, for example  $\beta$ -catenin, selectins, for example E-, P- and L-selectin, and their
- 20 receptors, CD44 (standard and splice variants), integrins and ICAMs.

- Genes preferred according to the invention for characterizing the ability to metastasize are
- 25 angiogenesis factors (bFGF and bFGF-R; VEGF and VEGF-Rs), proteases (UPA; PAI; MMPs; TIMPs), adherins (E-cadherin;  $\alpha$ -catenin;  $\beta$ -catenin; selectin-L and -R; CD44), motility factors SF-L and c-met and metastasis suppressor nm23.

- 30 The steroid hormone receptor genes preferably used according to the invention are the genes which code for the oestrogen, progesterone or androgen receptor (ER, PR or AR).

- 35 The characterization of drug resistance genes in circulating cancer cells is also of particular importance

002290" 62953460

according to the invention because cancer cells are frequently resistant to therapeutic agents, and some of them are multi-resistant, and characterization of these genes can contribute to assessing the prospects of success of particular cancer therapies. Examples of such drug resistance genes are MDR1 which codes for P-glycoprotein, and nm23, hMLH1, gp170, MRP1, the topoisomerase gene, the glutathione S-transferase pi gene, the LRP gene and genes which code for  $\alpha$ - or  $\beta$ -tubulin.

Drug resistance genes preferably investigated according to the invention are MDR1, MRP1, the topoisomerase II gene, the LRP gene, the  $\beta$ -tubulin gene and the glutathione S-transferase pi gene.

For characterizing a modulation of the immune response it is possible, for example, to make use of assessment of the T- and NK-cell-mediated cytotoxicity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). For this purpose it is possible to investigate immunological effector cells, in particular NK, H1/TH2 and CD8 cells on the one hand and circulating cancer cells on the other hand, for example for the TNF- $\alpha$  gene (tumour necrosis factor), genes which code for interferons, for example  $\alpha$ - and  $\gamma$ -IFN, FAS ligand and FAS receptor genes, perforin1, bcl-2, bax and granzymes. FAS-R and FAS-L, perforin and granzymes are preferred.

The proliferation and apoptosis properties of circulating cancer cells are investigated according to the invention on the basis of genes which correlate with the proliferation and apoptosis status of cells, in particular cancer cells. These include, inter alia, some of the abovementioned oncogenes and proto-oncogenes and tumour suppressor genes and mutated tumour suppressor

09485879.062200

genes which may - beyond the cancer-specific  
characterization - also contribute to the cancer-  
associated characterization because of their expression  
pattern. Recourse is had according to the invention to,  
5 for example, p53, genes which are inactivated (bcl-2;  
c-myc; bFGF, c-fos; HSP70; IL-6; MDR1; PCNA) or activated  
(Bax; FAS-L and -R; cyclins A, B1, D1, D2, D3, E or G;  
GADD45; GD-AIF; HIC1; IGF-BP3; mdm2; p21)  
transcriptionally and sequence-specifically by p53, genes  
10 which are expressed at the start of apoptosis and of cell  
cycle arrest (apart from p53 also TNF- $\alpha$ , TNF-R1, TNF-R2,  
DPC-4, IFN- $\gamma$  und FAS-L and -R) and genes which occur when  
there is unregulated growth such as erb-B2, EGF and other  
autocrine growth factors (TGF- $\alpha$ ; PDGF). Preference is  
15 given to Bax, FAS, cyclins, mdm2, p21, p16, bcl-2, c-myc,  
FGF, MDR1, TNF- $\alpha$ , IFN- $\gamma$ , erb-B2, EGF and other autocrine  
growth factors.

For tumour biological investigation, that is to say for  
20 characterizing a modulation of the immune response, the  
proliferation and apoptosis properties, cyclins, in  
particular the cyclins B1, D1 and E, Ki67, FAS-L, FAS-R,  
bax and/or bcl-2 are preferably investigated.

25 The investigation of a body fluid can take place by using  
known immunological methods. These include, for example,  
immunoprecipitation and competition experiments, immuno-  
fluorescence, immunohistochemical staining methods,  
Western blotting, flow cytometry, ELISA and the like, and  
30 mass spectrometric methods. Since immunological methods  
usually aim at particular antigen-antibody interactions,  
such methods are preferably used for investigating the  
body fluid for proteins, the proteins being in particular  
those expressed by the genes described previously.  
35 Antibodies possibly required for this purpose either are  
known to the skilled person or can be obtained by

002220 " 62858460



customary methods. Immunological methods are preferably used according to the invention for investigating blood and, in particular, bone marrow. It is possible with immunological methods in an advantageous manner to  
5 analyse the following proteins, for example: P53, ERB-B2 and tumour antigens using ELISA and similar methods; FAS ligand and FAS receptor, phosphatidylserine, cytokines, perforin, cytokeratins and cyclins with the aid of immunophenotyping.

10

A preferred possibility for the investigation according to the invention of body fluids is provided by nucleic acid analysis. This includes, for example, investigations of DNA or RNA, in particular mRNA, using techniques known  
15 to the skilled person, such as sequencing techniques, hybridization techniques, for example Northern or Southern blotting, hybridization on microchips, in particular methods based on the polymerase chain reaction (PCR) and also techniques in which the DNA or RNA to be  
20 investigated is firstly transcribed and/or translated in vitro. It is possible according to the invention to investigate every body fluid by means of nucleic acid analysis. Recourse is advantageously had to blood, especially when mRNA is investigated. It is, of course,  
25 also possible to employ a combination of different nucleic acid analyses to investigate a gene. A combination of immunological methods and nucleic acid analyses may also be advantageous.

30

Many of the cancer-specific and cancer-associated genes are preferably investigated on the basis of mRNA. A technique used for this purpose is direct hybridization of mRNA and/or cDNA (qualitatively/quantitatively) on a solid matrix (for example in the form of microchips) with  
35 immobilized oligonucleotides or immobilized streptavidin and biotinylated oligonucleotides. mRNA, cDNA or double-

09485979.052200

stranded PCR products are hybridized onto the latter. Various ways for introducing the signal are available, for example primer extension by labelled dNTP and ddNTP. The detection principle is chosen appropriate for the label: radioactivity, fluorescence, chemiluminescence or other methods known to the skilled person for this purpose.

Use is made in particular of a well-known technique which combines reverse transcription (RT) and the polymerase chain reaction (PCR) and is referred to hereinafter as RT-PCR. In this method, firstly the mRNA is isolated from the cells from a body fluid according to the invention. This is then transcribed with the aid of reverse transcriptase to cDNA which is subsequently amplified with the aid of the PCR. The PCR products obtained in this way can then be either subjected to a fragment analysis, where appropriate after suitable purification, sequenced directly or indirectly via further cloning cycles or else expressed in vitro. The investigated mRNAs are quantified via various internal controls, preferably in the form of cell equivalents or cloned cDNAs or cRNAs by fluorescence-labelled primers, by real-time PCR or by RNA hybridization on microchips. The cell-specific quantification of genes takes place via internal standards, in particular RNA (cDNA) independent of the cell type and coding, for example, for GAPDH,  $\beta$ -microglobulin, L32 or  $\beta$ -actin. The specificity is verified by comprehensive controls such as mismatch samples or sequencing of the cDNA.

The cancer-specific genes, which are preferably characterized on the basis of mRNA analyses on body fluids, are, in particular, the genes described above which are essentially not expressed in non-cancer cells in the body fluid investigated.

Cancer-associated genes are, as a rule, preferably characterized on the basis of mRNA analyses of body fluids. These include, in particular, the following genes: bFGF, bFGF-R, VEGF, VEGF-Rs, MMPs, TIMPs, MDR1, 5 MRP, LRP, topoisomerase II, glutathione S-transferase, progesterone receptor, Bax, bcl-2, FAS-L, FAS-R, mdm2, p21, p16, c-myc, TNF- $\alpha$ , IFN- $\gamma$ , erb-B2 and EGF.

10 A DNA analysis, in particular sequence analysis of genomic DNA, is usually preferred for the investigation for oncogenes and/or mutated tumour suppressor genes and may be advantageous in particular for characterizing the following genes: p53, ras family, erb-B2, c-myc, mdm2, BRCA1, BRCA2, APC, DCC, RB MSH2, MLH1, RET and LOH 15 investigations in various chromosome sections by numerous microsatellites.

Body fluids can be analysed in the state in which they have been obtained. However, the samples are usually 20 according to the invention firstly prepared by procedures known per se for the subsequent investigation by obtaining cells or cell-containing concentrates or cell-containing liquids from the body fluid. This applies in particular to nucleic acid analyses. Thus, for example, 25 in place of blood it is possible and advantageous to use certain cell-containing liquids derived therefrom or cell concentrates, for example the so-called Buffy coat or cell fractions after density centrifugation. The cells obtained from body fluid can then be investigated in 30 particular for those genes which are essentially not expressed in non-cancer cells in the body fluid investigated.

Cancer cells removed from the body fluid are usually 35 investigated according to the invention for investigating for genes which are also expressed by non-cancer cells in

002290" 62958460

the body fluid investigated or in investigations for genomic DNA.

Known methods can be employed for removing cancer cells, for example physical methods such as microfiltration or density gradient centrifugation, or antigen-specific immunoadsorption methods in which specific antibodies label the cancer cells in such a way that they can subsequently be sorted out. Suitable antibodies (for example anti-EGP) are provided, for example, with fluorescent and, in particular, magnetic markers so that on use of a cancer cell-specific antibody labelled in this way it is possible to isolate cancer cells after binding such antibodies in so-called cell sorters. For selecting suitable antibodies for the purposes of isolating particular cancer cells it is possible to have recourse to the characterization and identification of these cancer cells without previous isolation. The state in which the cancer cells are isolated is preferably viable and, in particular, capable of proliferation. In particular, the mRNA should be intact for the investigations described above.

The cell fractions obtained after a separation must then be quantified with reference to cell-type-independent markers (for example GAPDH,  $\beta$ 2-microglobulin, L32 or  $\beta$ -actin). A further possible demonstration of purity is through RNA which is specific for MNCs (mononuclear cells) (perforin, CD45). The various cell fractions obtained after separation (fraction A: MNC including the tumour cells; fraction B: MNC after removal of the tumour cells; fraction C: purified tumour cells) are then also compared with one another by investigating the removed cancer cells and carrying out the same investigation with non-cancer cells from the same individual for comparison. This means that the patient's own controls are included

002220 16285460

in the investigation.

In a particular embodiment of the present invention, single cancer cells are removed from the body fluid and are also investigated singly. It is possible for this purpose to analyse an altered genome of a single degenerate cell by genome amplification by a so-called single-cell PCR.

The isolation of circulating cancer cells is advantageously carried out for genomic investigations and the investigation for genes which are also expressed by non-cancer cells in the body fluid investigated, for example the following genes: DNA: p53, ras family, erb-B2, c-myc, mdm2, RB, APC, DCC, LOH investigations in various chromosome sections by numerous microsatellites: RNA: bFGF, bFGF-R, VEGF-Rs, MMPs, TIMPs, MDR1, MRP, LRP, topoisomerase, glutathione S-transferase, Bax, bcl-2, FAS, mdm2, p21, p16, c-myc, FGF, MDR1, TNF- $\alpha$ , IFN- $\gamma$  and EGF, AR, ER, EGP and SF.

Certain investigations according to the invention are preferably carried out on cell cultures. This can be done by isolating the circulating cancer cells in the manner described above and then cultivating them under suitable conditions. It is possible in particular with in vitro cultures to gain information on the tumour biology (for example the modulation of the immune response by cancer cells or the proliferation) of these cells.

Genes advantageously characterized using cancer cells cultivated in vitro are, for example, the following: Bax, FAS, cyclins, mdm2, p21, p16, bcl-2, c-myc, FGF, MDR1, TNF- $\alpha$ , IFN- $\gamma$ , erb-B2 and EGF.

The method according to the invention can be used

irrespective of the stage of a cancer. It can be employed alone or in combination with other cancer diagnostic methods such as imaging methods or methods based on conventional tumour markers. The method according to the invention can be employed for prevention, on the appearance of the first warning signs of cancer or, for example, after a cancer therapy for early recognition of recurrence. It is suitable for the characterization and identification of all types of cancer as long as corresponding circulating cancer cells are present in the body fluids investigated. These include, for example, abdominal cancer, anal cancer, pelvic cancer, bile duct cancer, uterine cancer, endometrial cancer, brain cancer, head and neck cancer, lip cancer, mouth cancer, kidney cancer, parotid cancer, tongue cancer, inguinal cancer, soft tissue cancer, lymphomas, leukaemias, multiple leukaemias, and preferably breast carcinomas, sarcomas, ovarian carcinomas, lung carcinomas, pancreatic carcinomas, colon carcinomas, rectal carcinomas, prostate carcinomas, liver carcinomas, bladder carcinomas, gastric carcinomas, thyroid carcinomas, cervical carcinomas, endometrial carcinomas, melanomas, non-Hodgkin lymphomas and chronic myeloid leukaemias.

Use of the method according to the invention is of particular interest for lymph node-sparing types of cancer because in this case conventional methods based on the investigation of lymph nodes fail. If circulating cancer cells are detected with NO tumours (for example a breast or colon carcinoma), specific statements about the choice of therapy are possible on the basis of the particular constellation. Thus, an adjuvant/curative therapy is preferably indicated in these cases, where appropriate with subsequent additional immunomodulatory therapy for advanced tumours.

Irrespective of whether investigation is only for cancer-specific or additionally for cancer-associated genes, it is preferred according to the invention to investigate for at least two different genes so that a method is made  
5 available according to the invention for multiple characterization of disseminated and micrometastasized cancer cells.

10 A first application of the method according to the invention is directed at detecting circulating cancer cells. For this purpose, the expression of cancer-specific genes is preferably measured. Multiparameter expression analyses of those genes which are switched off in non-cancer cells in the body fluid investigated are  
15 particularly preferred. These analyses may embrace up to about 40 genes. As a rule, up to about 25 genes, preferably about 2 to 10 genes and, in particular, about 3 to 7 genes are investigated. The corresponding mRNAs are preferably analysed, in particular by RT-PCR.

20 Particularly effective combinations comprise the CEA and CK20 genes, with analysis of the corresponding mRNAs being preferred. These combinations may, where appropriate, advantageously be supplemented by an  
25 investigation for MUC1, in which case the relation between the tumour-specific 336BP splice variant and the natural 309BP splice variant is analysed in particular. Investigations of this type can be used in particular for detecting circulating cancer cells of the carcinoma type.  
30 Preference is given in this connection to gynaecological carcinomas such as ovarian, breast or various uterine carcinomas, colon carcinomas, lung carcinomas, gastric carcinomas, thyroid carcinomas, bladder carcinomas, endometrial carcinomas, and prostate carcinomas. The  
35 investigation may take place without previous removal of the cancer cells. The MNC fraction is preferably used in

002260" 6258460

blood investigations.

Further effective combinations comprise the MAGE3 and tyrosinase genes, with analysis of the corresponding mRNAs being preferred. These combinations may, where appropriate, advantageously be supplemented by an investigation for Muc18. Investigations of this type can be used in particular for detecting circulating cancer cells of the melanoma type.

10

The aforementioned expression analyses can be supplemented by other methods for detecting cancer-specific genes. For this purpose, investigations for oncogenes and/or mutated tumour suppressor genes are preferably initiated, it being possible to have recourse in particular to the abovementioned genes of this type which are preferred according to the invention. Analyses of this type, in particular for detecting mutations, amplifications, LOHs, translocations or polymorphisms, are advantageously carried out at the DNA level, for example by DNA sequencing or hybridization techniques, and may embrace up to about 40 genes. As a rule, up to about 20 genes, preferably about 2 to 10 genes and, in particular, about 3 to 7 genes are investigated.

25

Particularly effective combinations comprise the p53 and/or erb-B2 genes. In this case, p53 is preferably investigated on the basis of the corresponding cDNA for mutations and/or LOH and erb-B2 is preferably investigated at the DNA level for amplifications. These combinations may, where appropriate, advantageously be supplemented by investigations for c-myc and/or K-ras, with c-myc preferably being investigated at the DNA level for amplification and K-ras being investigated for mutations, and/or by investigations for RB, APC, DCC and/or DPC4, preferably on the basis of LOHs.

35

09485879.062200



002290 62858460  
This first application can be supplemented by investigating the circulating cancer cells for genes which provide information about their origin, that is to say permit the source of spread to be localized to an organ. This can also take place in the form of multiparameter expression analyses in which organotypical morphogenes are measured. Analyses of this type may embrace up to about 36 genes. As a rule, up to about 14 genes, preferably about 1 to 8 and, in particular, 2 to 5 genes are investigated.

Particularly effective combinations comprise the maspin and/or PR genes, in particular for detecting breast carcinomas, with the corresponding mRNAs preferably being analysed. This combination can advantageously be supplemented by investigations for  $\beta$ -hCG and/or ER. An analogous statement applies to the detection of ovarian and cervical carcinomas, it being possible and advantageous in this case to supplement by an investigation for SCCA.

Further particularly effective combinations comprise the PSM and/or PSA genes, in particular for detecting prostate carcinomas, with the corresponding mRNAs preferably being analysed. This combination can advantageously be supplemented by investigations for hK2.

Further particularly effective combinations comprise the gastrin gene, in particular for detecting colon carcinomas, with the corresponding mRNA preferably being analysed. A combination of GIP and/or motilin also provides an effective possibility for detecting colon carcinomas.

Further particularly effective combinations comprise SP-A and SP-C, in particular for detecting lung carcinomas,

with the corresponding mRNA preferably being analysed. This combination can advantageously be supplemented by investigations for  $\beta$ hCG.

- 5 Further particularly effective combinations comprise EGF-R and  $\beta$ hCG, in particular for detecting bladder carcinomas.

10 A further application of the method according to the invention relates to drawing up a risk profile for detected circulating cancer cells, on the basis of which a prognosis can be made. The metastasizing properties of these cancer cells are preferably assessed for this purpose.

15 The tumour risk potential can additionally be described by analysing mutations and amplifications and/or enhanced/diminished expression of particular genes which influence the growth behaviour of the cancer cells (for  
20 example: c-myc, c-erb-B2, c-fos, erb-B, mdm2, nm23, p16, p21).

Another important factor for estimating the risk is the sensitivity of the tumour to immunological attacks by the  
25 organism involved. Apoptosis of the target cell (tumour cell) depends on many effector mechanisms. It is an enormous advantage for a tumour to withstand these defence mechanisms. Apoptosis-relevant genes may indicate the extent to which a tumour is resistant or sensitive to  
30 attacks by defence cells, or possibly even can itself mount attacks on the effector cells (for example: perforin, granzyme, bax, bcl-2, fas, fas-L, GADD45, p53, TNF-R1, TNF-R2).

35 Of equally great importance is quantification of the tumour cells in the blood. It is crucial for there to be

09485879.062200

a difference in the number of circulating tumour cells before and after a surgical intervention or therapy. Quantification of the cancer cells on the basis of the cancer-specific genes indicated above with the aid of longitudinal standards provides such information.

Multiparameter expression analyses are preferred for drawing up a risk profile of this type. These may embrace up to about 50 genes. As a rule, up to about 25 genes, preferably about 2 to 15 genes and, in particular, about 4 to 12 genes are investigated.

Particularly preferred for estimating the risk is assessment of the metastasizing properties; this is preferably aimed at the ability of the cancer cells to degrade matrix and control angiogenesis. In this connection, recourse is had in particular to the abovementioned angiogenesis factors and/or proteases, and their antagonists.

Particularly effective combinations for the characterization of the metastasizing properties comprise bFGF, bFGF-R, VEGF-R1 and/or VEGF-R2, where appropriate together with VEGF, with the corresponding mRNAs preferably being investigated. These combinations may, where appropriate, be supplemented by investigations for MMPs, in particular MMP2, and/or TIMPs, in particular TIMP3, with the corresponding mRNAs preferably being investigated in this case too.

Effective combinations for tumour biological investigation comprise the FAS-L and FAS-R genes, which are preferably investigated on the basis of the corresponding mRNAs. This combination can advantageously be supplemented by investigations for cyclins, in particular cyclin B1, D1 and E, Ki67, bax and/or bcl-2.

002290" 6283460

A particular advantage of the method according to the invention is that individual risk profiles can be drawn up for individual patients. Since the method is particularly suitable for continuous use, that is to say  
5 can be repeated at any time, valuable information about the development of a cancer can be obtained for an individual patient on the basis of the change in such risk profiles. Another advantage is that it is thus unnecessary to have recourse to statistics which are  
10 generally based on inquiries in which patients with very different conditions are averaged.

A further application of the method according to the invention relates to the therapy of a detected cancer.  
15 Thus, statements can be made about the choice and monitoring of and resistance to therapy.

Questions of importance for the choice of therapy relate to the type of therapy or the choice of medication. These  
20 include, for example, decisions as to whether the therapy is to be curative or palliative, adjuvant or risk-adapted, and assessment of the efficacy of an anticancer therapy. For example, anticancer agents (cytostatics) which lead to programmed cell death (apoptosis) can be  
25 tested for their efficacy by investigating apoptosis-associated genes. Particularly suitable for this purpose is analysis of various mRNAs of the apoptosis-associated genes described above. These tests are preferably carried out on circulating cancer cells which are cultivated in  
30 vitro. It is thus unnecessary to administer any cytostatics to the patient.

The present invention therefore also relates to the use of disseminated and micrometastasized cancer cells  
35 characterized according to the invention for testing active substances for an antineoplastic effect.

It is possible in principle to assess all anticancer therapies with the method according to the invention. These include, for example, vaccines, immunomodulation, molecular therapies such as gene replacement, antisense  
5 nucleotides, ribozymes, monoclonal antibodies, MMP inhibitors and attenuated viruses, for example E1B attenuated viruses for the cytolysis of p53wt-deficient cancer cells.

10 Since the method according to the invention is based on molecular biology investigations, it is outstandingly suitable for providing information concerning the choice of therapy adapted to the molecular endowment of the investigated cancer cells.

15 The assumption must be that a successful anticancer therapy will lead to a decrease and, in the most favourable case, to the complete disappearance of circulating cancer cells and/or to the loss of risk  
20 factors. If a type of cancer does not respond to a particular therapy, it must usually be assumed that the number of circulating cancer cells is not decreasing but, where appropriate, increasing or that the patient-specific risk is becoming greater. It is thus possible to  
25 assess the progress of a cancer and its therapy by repeated application of the method according to the invention. It is thus possible, by a time-dependent comparison, to assess the efficacy of a therapy and also identify in a simple manner resistance to particular  
30 types of therapy. The occurrence thereof may furthermore be confirmed by investigations of circulating cancer cells for drug resistance genes after administration of therapeutic agents to the patient.

35 Analysis of various genes which are the target of particular therapeutic agents, such as EGP (antibody

002250 62853460

against epithelial antigen), c-erb-B2 (anti-erb-B2 antibody mustard complex), MMP (anti-protease therapy), PR and ER (anti-hormone therapy), bFGF (anti-bFGF therapy) or topoisomerase II (doxorubicin inter alia) may provide information on the specific effect of the substances by direct quantification of the "target parameters". The success of a cytostatic therapy with microtubule-stabilizing taxanes (for example Taxol) can be predicted by detecting expression of the RNA of the monomeric target molecules ( $\alpha$ - and  $\beta$ -tubulins), whose assembly is prevented by Taxol. Resistance of cancer cells to cytostatics (for example cisplatin) can be detected through the loss of the expression of DNA repair genes (for example hMLH1). It is furthermore possible by generating in vitro systems for the effect of a wide variety of therapeutic agents to be pretested directly on a patient's own tumour cells in order to establish in this way the best possible type of treatment.

Particularly effective combinations for assessing a drug resistance which may exist comprise the MDR1, MRP, topoisomerase II and glutathione S-transferase pi genes, while measuring the corresponding mRNAs, for example. Supplementary investigation of  $\beta$ -tubulin mutations and MDR1 amplification is also possible. For the MDR1 investigation, recourse is frequently also had to analysis of the MDR1 pump gp170 and/or the MDR1 efflux doxorubicin test.

A particular advantage of the method according to the invention is that therapy-refractory cells (minimal residual disease; MRD) can be characterized and identified and, based on this, a therapeutic approach which has already been implemented can be extended in a risk-adapted manner to eliminate completely the residual cancer cells.

Although the method according to the invention has primarily been described with reference to the characterization of human genes, it is not intended to be restricted thereto. On the contrary, a number of other  
5 applications are evident to the skilled person, such as those in animal models to answer questions which correspond or are at least similar to those above.

The present invention also relates to means for carrying  
10 out the method according to the invention. Such means should be as easy as possible to manipulate and be essentially ready for use. Means for carrying out the method according to the invention are advantageously used in kit form, for example as test kit and/or diagnostic  
15 kit. A kit of this type comprises at least one compartment, for example a vial or test tube, in which the means for the investigation according to the invention for the above genes are present where possible in aliquoted amounts. The kit normally comprises a  
20 plurality of compartments, it being possible for one compartment to be assigned to the investigation for a particular gene, but may also comprise means which can be used to investigate the plurality of genes. In some circumstances, it is also possible for a plurality of  
25 compartments to be assigned to the investigation for a particular gene. The kit also comprises, where appropriate, another compartment to receive the sample of body fluid. Contact of the sample of body fluid with the means for carrying out the method according to the  
30 invention can take place, where appropriate, in a further compartment. The choice of the means depends on the genes investigated and the method chosen.

Diagnostic and/or test kits according to the invention  
35 may comprise means for preparing the sample of body fluid, for example means for concentrating cells from

09485879.062200

body fluids, such as density gradients and/or filters, means for isolating and purifying DNA and/or RNA from cells, in particular systems based on guanidine isothiocyanate, spin columns with suitable solid phases and/or oligo-dT systems; means for carrying out reverse transcription (RT), for example reverse transcriptase, RT buffer, RNase inhibitor, suitable primers and/or dNTPs; means for carrying out the PCR, for example thermostable polymerase, PCR buffer, MgCl<sub>2</sub> and/or dNTPs; means for carrying out restriction enzyme digestions (RD), for example restriction enzyme and RD buffer; and/or means for analysing the products obtained from RT, PCR and/or RD, for example gels or means for preparing appropriate gels, ELISAs and the like.

On the other hand, many of the means necessary for carrying out the above methods are also commercially available, often even in kit form, so that merely supplementary means are necessary for carrying out the method according to the invention. Supplementary kits according to the invention of this type preferably provide appropriate primers, probes and/or negative/positive controls and, where appropriate, further aids.

Preferred kits and supplementary kits according to the invention are those which make it possible to investigate for the gene combinations which have been described above and have emerged as effective. Kits of this type are used with the aim of detecting cancer in general, localizing primary tumours, carrying out an assessment of the risks and prognosis, or gaining information in relation to therapy. Kits of this type can be combined in a type of modular system for comprehensive assessment of a cancer.

On the other hand, kits according to the invention may



also comprise means making investigations possible for genes for cancer-specific and cancer-associated characterization of a particular type of cancer. For example, a melanoma-specific kit may comprise at least means for investigating for tyrosinase and bFGF, a colon-specific kit may comprise at least means for investigating for CK20, bFGF and MMP2 and a breast-specific kit may comprise at least means for investigating for CK19, bFGF, MMP2 and PR.

The following examples are intended to explain the invention in detail without restricting it.

**Reference Example 1:**

**Isolation of mononuclear cells (MNC) from blood**

A centrifuge tube (50 ml) is charged with 15 ml of density gradient medium (DGM) 1.077 (RT) which is cautiously overlaid with 30 ml of blood/PBS (heparinized or EDTA blood). After centrifugation (800 g, RT) for 30 minutes, all interphase cells (MNC) are transferred with a Pasteur pipette into a new centrifuge tube (15 ml) charged with 6 ml of PBS/add (PBS + BSA 0.2%, sodium azide 0.02%, EDTA 1 mM). From here on, all the steps are carried out cold (4°C). Centrifugation (600 g, 4°C, 10 min) is followed by taking up the cells in 10 ml of PBS/add, and the cell count is determined by Trypan blue staining (95 µl of TB solution + 5 µl of cell solution) (cell count = cell count from 16 small squares (Neubauer) x 2x10<sup>6</sup>). Centrifugation (400 g, 4°C, 10 min) is followed by the cells being taken up in ice-cold PBS/add and transferred into an Eppendorf tube (1.5 ml) (with a cell count of up to 2.5 E7 in 0.5 ml; with 2.5 E7 to 5E7 in 1 ml). Then, for RNA/DNA isolation, fraction A (1/4 vol. with 20 ml, 1/6 vol. with 30 ml) is removed, the cells present therein are centrifuged (400 g, 3 min), and the resulting pellet is resuspended in 600 µl of RLT-Me

buffer (from RNEasy Blood Kit Qiagen) and stored at -80°C. Finally, 10% strength FC blocking reagent is added.

5 **Reference Example 2:**

**Isolation of epithelial tumour cells from whole blood**

Anti-epithelial beads (40 µl/0.5 ml) are washed twice with 800 µl of PBS/add in a magnetic strip. 40 µl/0.5 ml of washed beads are placed in an Eppendorf tube, the tube is rotated in a rotor at 4°C for 25 min and then placed in a tube stand, and the suspension from the tube lead is put into the tube. The tube is placed in an MPC for 1 min, the cell suspension is discarded, the magnetic strip is removed (or the tube is taken out) and addition of 800 µl of PBS/add is followed by cautious resuspension. The last sequence of steps is repeated 6 times, finally resuspended in PBS/1 mM EDTA (without BSA). The tube is placed in an MPC for 1 min, and the supernatant is completely removed. The resulting beads with adherent cells form fraction C. For RNA/DNA isolation, this is resuspended in 200 µl of Trizol and stored at -80°C. Perforin mRNA can be measured as a purity marker for fraction C. Evaluation takes place by determining tumour-associated and tumour-specific RNA, and determining the RNA of the epithelial glycoprotein by quantifying the GAPDH RNA.

**Reference Example 3:**

**DNA/RNA isolation**

The DNA/RNA isolation is carried out in a manner known per se.

**Reference Example 4:**

**CK20 and CEA mRNA analysis by RT-PCR**

To detect epithelial cells in blood, the content of CK20 mRNA is determined organ-selectively (ovary, colon >

094485879.062200

breast) by molecular biological means with a sensitivity of more than one cell per  $10^6$  leukocytes. The CEA mRNA content is additionally investigated. This detection of cells which form the oncogenic adherin CEA was carried  
5 out with a sensitivity of one cancer cell per  $10^6$  leukocytes.

Outline of experiment

Reverse transcription (RT):

10 The following reagents are mixed (RT mix):

2.35  $\mu$ l of  $H_2O$

4  $\mu$ l of 5x first strand buffer

2  $\mu$ l of 0.1 M DTT

0.15  $\mu$ l of RNA guard (38950 U/ml)

15 0.5  $\mu$ l of random primer (500  $\mu$ g/ml)

0.5  $\mu$ l of dNTP mix (20 mM each)

0.5  $\mu$ l of M-MLV (200 U/ $\mu$ l)

10  $\mu$ l of RNA (about 1  $\mu$ g) isolated from mononuclear cells  
20 (5 ml of blood) are denatured at  $70^\circ C$  for 1 min,  
immediately cooled on ice for 3 min, mixed free of air  
bubbles with 10  $\mu$ l of RT mix, incubated at  $37^\circ C$  for 60  
min, incubated at  $95^\circ C$  for 3 min, immediately cooled on  
ice for 3 min and either subjected directly to PCR or  
25 frozen at  $-20^\circ C$ .

094455879.062200

PCR:

The following reagents are mixed per PCR mixture (µl):

	CK20	CEA
TaqMan buffer (10x)	5.0	5.0
5 MgCl <sub>2</sub> (25 mM)	8.0	8.0
dNTP (0.75 µl; 2.5 mM each)	3.0	3.0
Primer A (20 pmol/µl)	0.75	0.75
Primer B (20 pmol/µl)	0.75	0.75
TaqMan probe (20 pmol/µl)	0.5	0.5
10 Amplitaq-Gold (PE 5U/µl)	0.5	0.5
H <sub>2</sub> O	28.5	28.5
cDNA from RT	3.0	3.0

- 15 The PCR is carried out in the ABI 7700 sequence detector (TaqMan). A two-stage PCR method is used. The following temperature profile is utilized:

for CK20:

- 20 95°C 12 min (hot start activation)  
 95°C 30 sec  
57°C\* 60 sec 45x  
 20°C ∞

for CEA:

- 25 95°C 12 min (hot start activation)  
 95°C 30 sec  
58°C\* 60 sec 45x  
 20°C ∞

Controls:

- 30 Pos. (CK20): NCI-H508 adenocarcinoma cell line  
 Neg. (CK20): MES-SA/Dx5 uterine sarcoma cell line;  
 lymphocytes from a normal donor  
 Pos. (CEA): NCI-H508 adenocarcinoma cell line; MCF7  
 breast carcinoma cell line  
 35 Neg. (CEA): Lymphocytes from a normal donor

Primer:

	Primer A	Primer B	TaqMan probe
CK20	CK20 sense	CK20 antisense	CK20 probe
CEA	CEA sense	CEA antisense	CEA probe

5

Analysis of the PCR products:

The yield from the PCR taking place is measured on line in the sequence detector for each round of cycles. The curve recorded for the progress of the reaction serves as  
10 basis for determining the amount of the cDNA to be analysed as equivalent of the mRNA. This is based on determination of when the PCR changes to the exponential phase.

15 Reference Example 5:

**MUC1 mRNA analysis by RT-PCR**

The MUC1 mRNA is determined in order to assess the carcinoma-specific mucin transcription.

20 Outline of experiment

Reverse transcription (RT):

The following reagents are mixed (RT mix):

- 4 µl of 25 mM MgCl<sub>2</sub>
- 2 µl of PCR buffer II (10x)
- 25 2 µl of 10 mM dCTP
- 2 µl of 10 mM dGTP
- 2 µl of 10 mM dATP
- 2 µl of 10 mM dTTP
- 1 µl of RNase inhibitor (2000 U)
- 30 1 µl of M-MLV (5000 U)
- 1 µl of random hexamers (5 nmol)

5 µl of RNA (about 1 µg) isolated from mononuclear cells (5 ml of blood) are added to the RT mix and incubated at  
35 room temperature for 10 min, at 42°C for 15 min, at 99°C for 5 min and at 5°C for 5 min.

5

10

15

20

Controls:

25

Primers:

30

35

12 µl of formamide, 0.5 µl of Genescan Tamra 500 (PE) and 1 µl of PCR mixture are mixed, denatured at 95°C for 3 min, incubated on ice and analysed in an ABI Genescan

310 (anode buffer: 2% polymer, 1x genetic analyser  
buffer; cathode buffer: 3% polymer, 40% urea, 1x genetic  
analyser buffer; injection time: 10 s; injection voltage:  
7 kV; run voltage: 13 kV; run temperature: 30°C; running  
5 time: 18 min; module: Short Denatured C).

The peak areas for the PCR products (336 bp and 309 bp)  
are determined for the evaluation. The quotient of the  
peak areas for the 336 bp splice variant and the 309 bp  
10 splice variant is formed (0.2 is normal, up to 0.7  
corresponds to weak expression and > 0.7 to strong  
expression).

# **Reference Example 6:**

15 **GST pi, FAS-R, FAS-L, MMP-2 mRNA analysis by RT-PCR**

## **Outline of experiment:**

The reverse transcription (RT) is carried out as in  
Reference Example 4.

20 The following reagents are mixed per PCR mixture (µl):

	GST pi	FAS-R	FAS-L	MMP-2
PCR buffer II (10x)	5.0	5.0	5.0	5.0
ROX TIB-MOLBIOL (100 µM)	0.75	0.5	0.5	0.5
25 MgCl <sub>2</sub> (25 mM)	6.0	8.0	8.0	8.0
dNTP (0.75 µl each) 2.5 mM	3.0	3.0	3.0	3.0
Primer A (20 pmol/µl)	1.0	1.0	0.75	0.75
Primer B (20 pmol/µl)	1.0	1.0	0.75	0.75
TaqMan probe (20 pmol/µl)	0.5	0.3	0.5	0.5
30 Amplitaq-Gold (PE 5U/µl)	0.5	0.5	0.5	0.5
H <sub>2</sub> O	29.25	27.7	28.0	28.0
cDNA from RT	3.0	3.0	3.0	3.0

The PCR is carried out in an ABI 7700 sequence detector  
35 (TaqMan). A two-stage PCR method is used. The following

002290" 67855460

temperature profile is utilized:

for GST pi:

95°C 10 min (hot start activation)

95°C 30 sec

5 57°C 60 sec 40 x

20°C ∞

for FAS-R and FAS-L:

95°C 12 min (hot start activation)

95°C 30 sec

10 55°C 30 sec 45 x

20°C ∞

for MMP-2:

95°C 10 min (hot start activation)

95°C 30 sec

15 58°C 60 sec 45 x

20°C ∞

Number of cycles: (45 for FAS; MMP-2)

Controls:

20 Pos. (GST pi): MES

MNC (GST pi): The limit for normal expression is fixed using the value for CT for the MNC control.

25 Pos. (FAS-R): MNCs (normal donor); ES-2; MNC cDNA serial dilutions

Neg. (FAS-R): dist. H<sub>2</sub>O

Pos. (FAS-L): MNCs (normal donor); ES-2; MNC cDNA serial dilutions

30 Neg. (FAS-L): MCF-7 (breast carcinoma); Daudi (Burkitt's lymphoma)

Pos. (MMP-2): COLO-320

Neg. (MMP-2): SW403; lymphocytes from a normal donor

002200" 6285460



Primers:

	Primer A	Primer B	TaqMan probe
	GST pi sense	GST pi antisense	GST pi probe
	FAS-R sense	FAS-R antisense	FAS-R probe
5	FAS-L sense	FAS-L antisense	FAS-L probe
	MMP-2 sense	MMP-2 antisense	MMP-2 probe

Primer and probe sequences for FAS were designed in accordance with GenBank Accession # M67454; primer and probe sequences for FAS-L were designed in accordance with GenBank Accession # U08137.

Analysis of the PCR products:

In analogy to Reference Example 4.

Reference Example 7:

**bFGF-R, bFGF, VEGF-R2 mRNA analysis by RT-PCR**

Outline of experiment:

The reverse transcription (RT) is carried out as in Reference Example 1.

The following reagents are mixed per PCR mixture (µl):

	bFGF-R	bFGF	VEGF-R2
25	5.0	5.0	5.0
	0.5	0.5	0.5
	1	1	1
	1	1	1
	0.25	0.25	0.25
30	31.55	31.55	31.55
	5.0	5.0	5.0

The PCR is carried out in a Perkin Elmer 9600 or 2400 thermocycler. The following temperature profile is used:

95°C 5 min  
95°C 60 sec  
53°C 60 sec  
72°C 60 sec 45 x  
5 72°C 10 min

The PCR mixture is cooled to 4°C.

Controls:

10 Pos. (bFGF-R): ES-2 (ovarian carcinoma); NB-4  
(ApML); MCF-7 (breast carcinoma); 697  
(cALL); Colo 829 (melanoma)  
Neg. (bFGF-R): Lymphocytes (normal donor); NCI-H508  
(adenocarcinoma); K562 (CML)  
15 Pos. (bFGF): ES-2 (ovarian carcinoma); K562 (CML);  
MES-SA/Dx5 (uterine sarcoma); Colo  
829 (melanoma)  
Neg. (bFGF): Lymphocytes (normal donor); 697  
(cALL); NCI-H508 (adenocarcinoma)  
20 Pos. (VEGF-R2): ES-2 (ovarian carcinoma); Colo 829  
(melanoma); EFM192A (breast  
carcinoma)  
Neg. (VEGF-R2): Lymphocytes (normal donor); NCI-H508  
(adenocarcinoma)

25

Primers:

	Primer A	Primer B
bFGF-R	bFGF-R sense	bFGF-R antisense
bFGF-L	bFGF-L sense	bFGF-L antisense
30 VEGF-R2	VEGF-R2 sense	VEGF-R2 antisense

Analysis of the PCR products

- a) 20-30  $\mu$ l of the PCR mixture are fractionated on a 2% agarose gel (1xTBE).
- 35 b) 6-10  $\mu$ l of the PCR product are incubated with (+) or without (-) restriction enzyme at 37°C for 1 hour.

After fractionation in a 2% agarose gel, two smaller fragments are to be seen.

	Restriction	+	-
5	Reagents	6 (10) µl PCR product 0.5 µl R enzyme 1 (1.5) µl buffer M 2.5 (3) µl dist. H <sub>2</sub> O	6 (10) µl PCR product - 1 (1.5) µl buffer M 3 (3.5) µl dist. H <sub>2</sub> O

**Reference Example 8:**

**Tyrosinase mRNA analysis by RT-PCR**

10

**Outline of experiment:**

The reverse transcription (RT) is carried out as in Reference Example 1.

15 The following reagents are mixed per PCR mixture (µl):

		1st round	2nd round
	PCR buffer (10x)	5.0	5.0
	MgCl <sub>2</sub> (0.1 M)	0.8	0.8
	Triton X-100 (1%)	5.0	5.0
20	dNTP (20 mM)	0.5	0.5
	Primer A (20 pmol/µl)	7.5	-
	Primer B (20 pmol/µl)	7.5	-
	Primer C (20 pmol/µl)	-	7.5
	Primer D (20 pmol/µl)	-	7.5
25	Taq polymerase (5U/µl) + Taq antibody 1:1	1.0	1.0
	H <sub>2</sub> O	20.7	20.7
	cDNA from RT	2.0	-
	PCR product from 1st round	-	2.0*

30 \* Dilute positive control 100-fold

The PCR is carried out in a Perkin Elmer 9600 or 2400

thermocycler. The following temperature profile is used:

95°C 10 min  
95°C 60 sec  
5 60°C 30 sec  
72°C 60 sec 30 x  
72°C 10 min

The PCR mixture is cooled to 4°C.

10

Controls:

Pos. (tyrosinase): COLO-829 cDNA (human melanoma); 697  
cDNA (pre-B-cell leukaemia)

15 Neg. (tyrosinase): Premix without sample DNA  
(obligatory); MES (uterine sarcoma);  
LNCAP (prostate carcinoma)

Primers:

	Primer A	Primer B	Primer C	Primer D
20 Tyrosinase	HTYR-1	HTYR-2	HTYR-3	HTYR-4

Analysis of the PCR products:

10 µl of PCR product and 1.1 µl of sample buffer are  
subjected together with 10 µl of 100 bp ladder to an  
25 agarose gel electrophoresis with a run voltage of  
150 volts and a running time of 20 min. Evaluation takes  
place under a UV lamp at 254 nm or 312 nm.

The PCR product after the 1st round has a size of 284 bp.

The PCR product after the 2nd round has a size of 207 bp.

30 The 100 bp ladder is used as length standard.

09485879 052200

**Reference Example 9:**

**erb-B2, c-myc and mdrl amplification analysis**

The erb-B2, c-myc and mdrl genes and the  $\beta$ -globin gene are coamplified using fluorescein-labelled oligonucleotide primers. The amplicons are fractionated by capillary electrophoresis.

**Outline of experiment:**

The following reagents are mixed per PCR mixture ( $\mu$ l):

	erb-B2	c-myc	mdrl
PCR buffer (10x, PE)	5.0	5.0	5.0
MgCl <sub>2</sub> (25 mM, PE)	4.0	4.0	0.5
dNTP (20 mM)	0.25	0.25	0.25
(NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub> (100 mM)	7.5	7.5	7.5
Primer A (20 pmol/ $\mu$ l)	1.5	2.0	5.0
Primer B (20 pmol/ $\mu$ l)	1.5	2.0	5.0
Primer C (20 pmol/ $\mu$ l)	0.5	0.2	0.5
Primer D (20 pmol/ $\mu$ l)	0.5	0.2	0.5
Amplitaq-Gold (PE, 5U/ $\mu$ l)	0.4	0.4	0.25
H <sub>2</sub> O (double-distilled)	25.85	25.45	23.5
DNA	3.0	3.0	2.0

The PCR is carried out in a Perkin Elmer 2400, 9600 or 9700 thermocycler. The following temperature profile is used:

for erb-B2 and c-myc:

95°C      10 min

95°C      1 min

60°C      1 min

72°C      1 min      32 x

72°C      3 min

for mdrl:

94°C      5 min

95°C      1 min

57°C            1 min  
72°C           1 min        35 x  
72°C            5 min

5    The PCR mixture is cooled to 4°C.

Controls:

Pos. (erb-B2): DNA-A

Norm. (erb-B2): human DNA

10   Pos. (c-myc): DNA-B; H82-DNA

Norm. (c-myc): human DNA

Pos. (mdr1): CCRF-DNA

Norm. (mdr1): human DNA

15   Primers:

	Primer A	Primer B	Primer C	Primer D
erb-B2	Hex-neu-3	neu-5	PCO-3F	PCO-4
c-myc	Hex-myc-1	myc-2	PCO-3F	PCO-4
mdr1	Hex-mdr1-5F	mdr1-5B	PCO-3F	PCO-4

20

Analysis of the PCR products:

The PCR products are loaded onto a 2% agarose gel. After the capillary electrophoresis (Genetic-Analyzer ABI 310), the quotient of the area integral for erb-B2, c-myc or mdr1 and the area integral for  $\beta$ -globin is formed for each patient's sample and the controls. There is erb-B2, c-myc or mdr1 amplification in a patient's sample if the quotient is "significantly" larger than that of the normal control or of samples measured at the same time.

30

002290"62954460

**Reference Example 10:**

**DCC, APC, RB, p53, microsatellite (DxSy) LOH analyses**

Outline of experiment:

5 The following reagents are mixed per PCR mixture (µl):

	DCC	APC	RB	p53	DxSy
PCR buffer (10x)	5.0	5.0	5.0	5.0	3.0
dNTP mix (20 mM; 10 mM for DxSy)	0.5	0.5	0.5	0.5	4.8
10 MgCl <sub>2</sub> (25 mM)	-	-	-	3.0	3.0
Primer A (20 pmol/µl)	0.5	0.5	0.5	0.5	0.6
Primer B (20 pmol/µl)	0.5	0.5	0.5	0.5	0.6
Taq polymerase (5U/µl) + Taq antibody 1:1	0.5	0.5	0.5	0.5 **	0.3 **
15 H <sub>2</sub> O	40.0	40.0	40.0	37.0	14.7
DNA*	3.0	3.0	3.0	3.0	3.0

\* 3 µl of DNA (fraction C; tumour cell fraction; smear) 1 µl of DNA (fraction A) + 2 µl of H<sub>2</sub>O

20 \*\* Taq polymerase Amplitaq Gold

The PCR is carried out in a Perkin Elmer 9600 or 2400 thermocycler. The following temperature profile is used:

25 For DCC, APC and RB:

95°C      5 min  
 94°C      30 sec  
 53°C      30 sec  
72°C      30 sec      30 x

30 72°C      5 min

For p53:

94°C      10 min  
 94°C      30 sec  
 60°C      30 sec  
 35 72°C      30 sec      40 x  
 72°C      5 min

002290.6288460

For DxSy:

95°C      10 min  
 94°C      1 min  
 60°C      30 sec (D17S849 / D19S960)  
 5    53°C      30 sec (D16S265 / D11S528)  
 57°C      30 sec (D17S926 / D17S960)  
72°C      30 sec      40 x  
 72°C      10 min

10    The PCR mixture is cooled to 4°C.

Controls:

Neg.: Mixture without DNA

15    Primers:

	Primer A	Primer B
DCC-LOH	Hex-DCC LOH-1	DCC LOH-2
RB-LOH	FAM-RB LOH-1	RB LOH-2
APC-LOH	FAM-APC LOH-1	APC LOH-2
20    p53-LOH	FAM-p53 LOH-A	p53 LOH-B
D17S926-LOH	FAM-D17S926 a	D17S926 s
D17S695-LOH	FAM-D17S695 a	D17S695 s
D17S849-LOH	FAM-D17S849 a	D17S849 s
D17S960-LOH	FAM-D17S960 a	D17S960 s
25    D16S265-LOH	FAM-D16S265 a	D16S265 s
D11S528-LOH	FAM-D11S528 a	D11S528 s

Analysis of the PCR products:

1. PCR function detection in an agarose gel

30    9 µl (15 µl for DxSy) of PCR product and 1 µl (2 µl) of  
 10x TBE sample buffer with bromophenol blue are loaded  
 onto a 2% agarose gel (10 µl of ethidium bromide stock  
 solution 10 mg/ml per 100 ml of gel) in 1 x TBE buffer.  
 The electrophoresis is carried out at a constant voltage  
 35    of 160 to 170 V.

002290"6298460



2. Detection of allele loss using an ABI 310

12 µl of formamide, 1 µl of sample and 0.5 µl of Genescan  
Tamra 500 (PE) are denatured at 95°C for 2 min and  
immediately placed on ice. A fragment analysis is then  
carried out in an ABI 310 (analysis buffer; anode and  
cathode: 1x fragment analysis buffer (PE) with EDTA;  
polymer: POP-4; injection time: 5 sec; injection voltage:  
15 kV; voltage during the run: 15 kV; temperature during  
the run: 60°C; running time: 24 min; matrix: GS POP4C).

The analysis is carried out both in whole blood, which  
reflects the ratio of alleles in normal cells, and in  
fraction C which representatively indicates the condition  
of the cancer cells. Successful analysis is possible only  
if the patient is heterozygous for both alleles of a  
marker. The alleles differ in size by at least 4 bp. The  
quotients of the peak areas for the two alleles (allele  
1/allele 2) in the whole blood fraction are compared with  
those for fraction C. If the values differ by at least  
50%, an LOH can be assumed.

Reference Example 11:

**p53 and K-ras mutation analyses**

002230" 52853460

Outline of experiment:

The following reagents are mixed per PCR mixture (µl):

	Cod. 175	Cod. 245	Cod. 248	Cod. 249	Cod. 273	k-ras
PCR buffer (10x)	5.0	5.0	5.0	5.0	5.0	5.0
dNTP mix (20 mM)	0.5	0.5	0.5	0.5	0.5	0.5
DMSO	-	-	2.5	2.5	-	-
MgCl <sub>2</sub> (25 mM)	-	-	-	-	-	6.0
Primer A (20 pmol/µl)	1.0	1.0	1.0	1.0	1.0	1.0
Primer B (20 pmol/µl)	1.0	1.0	1.0	1.0	1.0	1.0
Taq polymerase (5U/µl) + Taq antibody 1:1	0.5	0.5	0.5	0.5	0.5	0.5
H <sub>2</sub> O	37.0	37.0	34.5	34.5	37.0	31.0
DNA	5.0	3.0	5.0	5.0	3.0	5.0

The PCR is carried out in a Perkin Elmer 9600 or 2400 thermocycler. The following temperature profile is used:

95°C      5 min  
 94°C      30 sec  
 55°C      30 sec  
72°C      30 sec      37 (for k-ras 35) x  
 72°C      5 min

The PCR mixture is cooled to 4°C.

Controls:

Pos. (p53; 248): DNA of acute promyelocytic leukaemia  
                          cell line NB-4; DNA of colon carc-  
                          inoma cell lines Colo 320  
 Pos. (p53; 273): SW480 colon carcinoma cells  
 Pos. (K-ras): SW480 and SW403 colon carcinoma cells  
 Neg. (p53): Mixture without DNA; mixture without  
                          restriction

Neg. (K-ras): Normal lymphocyte DNA or DNA of a negative cell line

Primers:

5		Primer A	Primer B
	p53 (175)	FAM-p53 175-S	p53 6-2
	p53 (245)	FAM-p53 245-A	p53 245-S
	p53 (248)	FAM-p53 7-1	p53 8-2
	p53 (249)	FAM-p53 7-1	p53 8-2TET-p53 8-2
10	p53 (273)	p53 273-S	TET-p53 8-2
	k-ras	k-ras sense	FAM-labelled K-105 antisense

Analysis of the PCR products:

15 1. PCR function detection in an agarose gel  
9 µl of PCR product and 1 µl of 10x TBE sample buffer with bromophenol blue are loaded onto a 2% agarose gel (10 µl of ethidium bromide stock solution 10 mg/ml per 100 ml of gel) in 1 x TBE buffer. The electrophoresis is  
20 carried out at a constant voltage of 160 to 170 V.

2. Restriction digestion  
7.3 µl of H<sub>2</sub>O (double-distilled), 2.0 µl of 10x buffer, 0.2 µl of 100 x BSA, 0.5 µl of restriction enzyme and  
25 10 µl of PCR product (for codon 245, 249 and 273: 7.5 µl of H<sub>2</sub>O (double-distilled), 2.0 µl of 10x buffer, 0.5 µl of restriction enzyme and 10 µl of PCR product; for codon 248: 7.75 µl of H<sub>2</sub>O (double distilled), 2.0 µl of 10x buffer, 0.25 µl of restriction enzyme and 10 µl of PCR  
30 product) are incubated at 37°C for 1 hour.

Depending on the amount of the PCR product, a 4% MetaPhor gel or an ABI 310 is used for the evaluation.

35 *Evaluation using MetaPhor agarose gel:*

18 µl of restricted PCR product and 2 µl of 10x TBE

sample buffer with bromophenol blue are loaded onto a 4% MetaPhor agarose gel (10 µl of ethidium bromide stock solution 10 mg/ml per 100 ml of gel) in 1 x TBE buffer. The electrophoresis is carried out at a constant voltage of 160 to 170 V. For comparison, the uncut PCR product from an arbitrary sample is also loaded onto each gel.

*Detection using an ABI 310*

12 µl of formamide, 1 µl of sample and 0.5 µl of Genescan Tamra 500 (PE) are denatured at 95°C for 2 min and immediately placed on ice. A fragment analysis is then carried out in an ABI 310 (analysis buffer; anode and cathode: 1x fragment analysis buffer (PE) with EDTA; polymer: POP-4; injection time: 5 sec; injection voltage: 15 kV; voltage during the run: 15 kV; temperature during the run: 60°C; running time: 24 min; matrix: GS POP4C).

Fragment lengths:

**Codon 175**

Wild type : 70 bp    227 bp    18 bp  
Mutated:    88 bp    227 bp

**Codon 245**

Wild type: 145 bp    23 bp  
Mutated:    168 bp

**Codon 248**

Wild type:    77 bp  
Mutated:    246 bp

**Codon 249**

Genotype:

Wild type:    81 bp  
Mutated:    147 bp

**Codon 273**

Wild type: 116 bp    21 bp  
Mutated:    137 bp

**K-ras codon 12**

Wild type: 114 bp      29 bp      14 bp  
Mutated: 143 bp      14 bp

- 5 For the evaluation, the 88 bp to 70 bp, 168 bp to 145 bp, 246 bp to 77 bp, 147 bp to 81 bp, 137 bp to 116 bp or 143 bp to 114 bp area integral is formed.

**Example 1 (Diagnostic query)**

- 10 a) Initial clinical situation

The patient to be investigated had mastopathy with suspected breast carcinoma. A blood sample was taken.

- b) Query

- 15 Were there any circulating cancer cells able to form metastases in the blood sample taken?

- c) Investigations and results

	Investigation	Result
	p53 mutation in tumour cells	NEGATIVE
20	p53(exon5) mutation	NEGATIVE
	p53(exon6) mutation	NEGATIVE
	p53(exon7) mutations	NEGATIVE
	p53(exon8) mutations	NEGATIVE
	erb-B2 after tumour cell isolation	POSITIVE
	c-myc after tumour cell isolation	POSITIVE
25	CK20 mRNA	POSITIVE
	CEA mRNA	POSITIVE
	MUC1 mRNA	0.95
	MUC1 mRNA fraction C	1.40
	bFGF mRNA	NEGATIVE
30	bFGF-R mRNA	POSITIVE
	VEGF mRNA	POSITIVE
	VEGF-R1 mRNA	POSITIVE
	VEGF-R2 mRNA	NEGATIVE

TIMP3 mRNA	NEGATIVE
MMP2 mRNA	NEGATIVE
Progesterone R mRNA	POSITIVE
Maspin mRNA	POSITIVE
5 Perforin after tumour cell isolation	NEGATIVE

d) Assessment

Cells which may be of the carcinoma type were detectable in the patient's blood circulation. Cancer cell-specific detection showed cells with enhanced transcription of the cancer-specific splice variant of the mucin1 gene. These cells also expressed CEA and CK20 mRNA. Since these expression characteristics are found in cases of breast carcinoma, the cells very probably originated from the breast, which was confirmed by the expression of maspin. The tumour cells could be concentrated in fraction C (MUC1) without lymphocytic contamination (perforin-negative). The detected cells also showed signs of an ability to metastasize because they expressed the bFGF and VEGF receptors, as well as VEGF, all of which are prerequisites for neoangiogenesis. The cells which have strayed into the blood expressed the progesterone receptor. The c-myc and erb-B2 amplification moreover indicated a poor prognosis. Qualitatively, this was a typical high-risk course with a huge potential for growth because these genes code for growth signals in the cancerous tissue.

e) Summary and conclusion:

Overall, the findings indicated a spreading carcinoma with a poor prognosis based on the mastopathy.

**Example 2 (Identification of the source of spread)**

a) Initial clinical situation

The patient to be investigated was suspected of having a colon or prostate carcinoma. A blood sample was taken.

b) Query

Were there any circulating cancer cells able to form metastases in the blood sample taken? Did these cells originate from a prostate or colon carcinoma?

5 c) Investigations and results:

	Investigation	Result
	K-ras after tumour cell isolation	POSITIVE
10	K-ras(exon1) mutation	POSITIVE
	K-ras(exon1) mutation	NEGATIVE
	CK20 mRNA	POSITIVE
	CEA mRNA	NEGATIVE
	MUC1 mRNA	> 1.00
15	Gastrin mRNA	POSITIVE
	PSM mRNA	NEGATIVE
	bFGF mRNA	NEGATIVE
	bFGF-R mRNA	POSITIVE
	VEGF mRNA	NEGATIVE
20	VEGF-R1 mRNA	NEGATIVE
	VEGF-R2 mRNA	NEGATIVE
	EGP mRNA	255370 (corresponds to 100%)
	GAPDH mRNA	125836424 (corresponds to 100%)
	EGP mRNA fraction C	1773 (corresponds to 0.7% of fraction A)
25	GAPDH mRNA fraction C	625 (corresponds to 0.0005% of fraction A)

d) Assessment

Cells spreading in the blood and transcribing exclusively  
30 the tumour-specific splice variant of the MUC1 gene as

well as CK20, which are therefore to be assigned to the carcinoma type, were detectable. They could be concentrated in fraction C. The cells spreading in the blood certainly originated from the colon because gastrin mRNA was detectable, in contrast to prostate-specific PSM mRNA.

The point-mutated oncogene k-ras which is typical of colon carcinomas was also found in the epithelial cell fraction C. The detected cells likewise showed signs of an ability to metastasize because they expressed the bFGF receptor, a prerequisite for neoangiogenesis.

e) Summary and conclusion:

Overall, the findings indicated a spreading carcinoma certainly to be found in the colorectal region. Therapy with Panorex appeared to be indicated because the cells expressed the EGP gene which is the therapeutic target.

**Example 3 (Prognosis)**

a) Initial clinical situation

The patient to be investigated had a malignant melanoma in the postoperative state (Clark II-III). A blood sample was taken.

b) Query

Were there any circulating cancer cells able to form metastases in the blood sample taken? Was it possible to make any other prognostic statements about the tumour?

c) Investigations and results:

Investigation	Result
p53 mutation in tumour cells	POSITIVE
p53(exon5) mutation	POSITIVE
p53(exon6) mutation	NEGATIVE
p53(exon7) mutations	NEGATIVE
p53(exon8) mutations	NEGATIVE
Tyrosinase mRNA	POSITIVE
MAGE3 mRNA	POSITIVE



	Muc18 mRNA	POSITIVE
	bFGF mRNA	NEGATIVE
	bFGF-R mRNA	POSITIVE
	VEGF mRNA	POSITIVE
5	VEGF-R1 mRNA	POSITIVE
	VEGF-R2 mRNA	NEGATIVE
	MMP2 mRNA	POSITIVE
	FAS mRNA in fraction C	POSITIVE
	FAS receptor mRNA in fraction C	NEGATIVE
10	Perforin after tumour cell isolation	NEGATIVE

#### d) Assessment

The results indicated a progressive malignant melanoma with cells spreading in the blood and capable of metastasizing. The ability of the cells circulating in the blood to metastasize was indicated by the expression of the angiogenesis factors bFGF receptor, VEGF receptor 1 and VEGF, as well as the ability of the circulating cells to degrade matrix (detection of MMP2 mRNA).

A protein-relevant mutation of the oncogene p53 was found in Exon 5 in fraction C. The cells expressed only the FAS ligand but not the FAS receptor; they were possibly not accessible to cell-mediated cytotoxicity (apoptosis). Lymphocytic contamination of fraction C was ruled out because perforin was undetectable.

#### Example 4 (Relevance to therapy)

##### a) Initial clinical situation

The patient to be investigated had a diagnosis of breast carcinoma (pT1b N1 M0). A blood sample was taken.

##### b) Query

Were there any circulating cancer cells able to form metastases in the blood sample taken? Was there any drug resistance?

c) Investigations and results:

Investigation	Result
p53 mutation in tumour cells	POSITIVE
p53(exon5) mutation	NEGATIVE
p53(exon6) mutation	NEGATIVE
p53(exon7) mutations	NEGATIVE
p53(exon8) mutations	POSITIVE
CK20 mRNA	POSITIVE
CEA mRNA	POSITIVE
MUC1 mRNA	0.90
MUC1 mRNA fraction C	1.40
bFGF mRNA	NEGATIVE
bFGF-R mRNA	POSITIVE
VEGF mRNA	POSITIVE
VEGF-R1 mRNA	POSITIVE
VEGF-R2 mRNA	NEGATIVE
Maspin mRNA	POSITIVE
MDR1 efflux doxorubicin test	55% (Ref.: 40 - 65%)
MDR1 pump gp170	61% (Ref.: 40 - 65%)
MDR1 (human genome)	NEGATIVE
MDR mRNA fraction C	NEGATIVE
MRP mRNA fraction C	NEGATIVE
GST pi mRNA fraction C	NEGATIVE
Topoisomerase II mRNA fraction C	POSITIVE

d) Assessment

Cells which may be of the carcinoma type were detectable in the patient's blood circulation. Cancer cell-specific detection showed cells with enhanced transcription of the cancer-specific splice variant of the mucin1 gene. These cells also expressed CEA and CK20 mRNA. Since these expression characteristics are found in cases of breast carcinoma, the cells very probably originated from the breast, which was confirmed by the expression of maspin. The detected cells also showed signs of an ability to metastasize because they expressed the bFGF and VEGF

receptors, as well as VEGF, all of which are prerequisites for neoangiogenesis. A p53 mutation in Exon 8 was also detectable in the tumour cell fraction. This is likewise a finding typical of breast carcinoma.

5

e) Summary and conclusion:

Overall, the findings indicated a carcinoma capable of metastasis. There was no evidence of drug resistance in the patient. On the basis of the detected expression of topoisomerase as target gene, anthracycline therapy appeared to be indicated.

10

**Example 5 (before chemotherapy)**

15 a) Initial clinical situation

The patient to be investigated had a diagnosis of breast carcinoma. The patient was not receiving chemotherapy. A blood sample was taken.

20 b) Query

Were there any circulating cancer cells able to form metastases in the blood sample taken? Was there any drug resistance?

c) Investigations and results:

25

Investigation	Result
p53 mutation in tumour cells	NEGATIVE
p53(exon5) mutation	NEGATIVE
p53(exon6) mutation	NEGATIVE
p53(exon7) mutations	NEGATIVE
30 p53(exon8) mutations	NEGATIVE
erb-B2 after tumour cell isolation	NEGATIVE
c-myc after tumour cell isolation	NEGATIVE
CK20 mRNA	POSITIVE
CEA mRNA	POSITIVE
35 MUC1 mRNA	0.55
bFGF mRNA	NEGATIVE

	bFGF-R mRNA	NEGATIVE
	VEGF mRNA	NEGATIVE
	VEGF-R1 mRNA	NEGATIVE
	VEGF-R2 mRNA	NEGATIVE
5	MDR1 pump gp170	18% <sup>1)</sup> (Ref.: 40 - 65%)
	MDR1 (human genome)	NEGATIVE
	MDR1 mRNA	POSITIVE
	GST pi mRNA	POSITIVE
	Topoisomerase II mRNA	POSITIVE
10	MRP mRNA	POSITIVE
	EGP mRNA	30743 (corresponds to 100%)
	GAPDH mRNA	1765600 (corresponds to 100%)
	EGP mRNA fraction C	1
	GAPDH mRNA fraction C	0
15	MUC1 mRNA fraction C	> 1.00
	bFGF mRNA fraction C	0.00

1) Nonspecific antibody-binding capacity (ABC): 953  
Specific ABC: 2935

20

#### e) Assessment

Cells of the carcinoma type which transcribed the cancer-specific splice variant of the MUC1 gene were detectable in the patient's blood circulation. Expression of CEA and CK20 was also detectable. These expression characteristics indicated a breast carcinoma. Since analysis of the above angiogenesis factors had negative results, it was possible to assume that the circulating cancer cells showed only a low potential for metastasis.

25 There was no evidence of drug resistance in the patient.

30

#### e) Summary and conclusion:

Overall, the findings indicated a spreading breast carcinoma without signs of drug resistance.

**Example 6 (after chemotherapy)**

a) Initial clinical situation

The patient was the same one as described in Example 5.

On the basis of the findings in Example 5, the patient

5 was treated with an adjuvant chemotherapy and with tamoxifen. Blood was again taken from the patient after completion of the chemotherapy.

b) Query

Were there any circulating cancer cells able to form

10 metastases in the blood sample taken?

c) Investigations and results:

	Investigation	Result
	anti-p53	low
	Pan p53	243 pg/ml normal up to 646 marginal up to 786 pathological above 787
15	c-erb-B2	2610 HNU/ml normal up to 3385 marginal 3386 - 3845 pathological >3845
	p53 mutation in tumour cells	NEGATIVE
	p53(exon5) mutation	NEGATIVE
	p53(exon6) mutation	NEGATIVE
20	p53(exon7) mutations	NEGATIVE
	p53(exon8) mutations	NEGATIVE
	erb-B2 after tumour cell isolation	NEGATIVE
	c-myc after tumour cell isolation	NEGATIVE
25	CK20 mRNA	NEGATIVE
	CEA mRNA	NEGATIVE
	MUC1 mRNA	0.60
	bFGF mRNA	NEGATIVE
30	bFGF-R mRNA	POSITIVE
	VEGF mRNA	weak positive

	VEGF-R1 mRNA	POSITIVE
	VEGF-R2 mRNA	NEGATIVE
	TIMP3 mRNA	NEGATIVE
	MMP2 mRNA	NEGATIVE
5	Progesterone R mRNA	POSITIVE
	EGP mRNA	232255 (corresponds to 100%)
	GAPDH mRNA	463040096 (corresponds to 100%)
	EGP mRNA fraction C	0
	GAPDH mRNA fraction C	203 (corresponds to 0.00004% of fraction A)
10	MUC1 mRNA fraction C	0.00

d) Assessment

Cells which may be of the carcinoma type were detectable in the patient's blood circulation. Cancer cell-specific detection showed cells with enhanced transcription of the cancer-specific splice variant of the mucin1 gene. The detected cells showed first signs of an ability to metastasize; they expressed bFGF-R, VEGF and VEGF-R1 mRNA; however MMP-2 was undetectable. The cells which had strayed into the blood were progesterone receptor-positive.

Of the prognostic oncoproteins, anti-p53 was detectable; this reactive protein due to p53 mutations indicated a worse prognosis.

e) Summary and conclusion:

Overall, the findings indicated a carcinoma still spreading. However, the picture showed a distinct change from the previous findings (before chemotherapy). Thus, in particular, MUC1 was no longer detectable in fraction C, and the markers CK20 and CEA were negative in fraction A. This indicated a distinct success of the therapy.

**Example 7**

a) Initial clinical situation

The patient to be investigated was suspected of having an

ovarian carcinoma. A blood sample was taken.

b) Query

Were there any circulating cancer cells able to form metastases in the blood sample taken? Was there any drug resistance?

5

c) Investigations and results

10

15

20

25

Investigation	Result
anti-p53	NEGATIVE
Pan p53	440 pg/ml normal up to 646 marginal up to 786 pathological above 787
c-erb-B2	2641 HNU/ml normal up to 3385 marginal 3386 - 3845 pathological >3845
p53 mutation in tumour cells	NEGATIVE
p53(exon5) mutation	NEGATIVE
p53(exon6) mutation	NEGATIVE
p53(exon7) mutations	NEGATIVE
p53(exon8) mutations	NEGATIVE
erb-B2 after tumour cell isolation	NEGATIVE
c-myc after tumour cell isolation	NEGATIVE
CK20 mRNA	NEGATIVE
CEA mRNA	NEGATIVE
MUC1 mRNA	0.35
bFGF mRNA	NEGATIVE
bFGF-R mRNA	NEGATIVE
VEGF mRNA	not assessable
VEGF-R1 mRNA	NEGATIVE
VEGF-R2 mRNA	NEGATIVE
Progesterone R mRNA	weak positive

002290 5283460

	MDR1 mRNA	POSITIVE
	Topoisomerase II mRNA	NEGATIVE
	MDR1 efflux doxorubicin test <sup>1)</sup>	0%
5	MDR1 pump gp170 <sup>2)</sup>	0%
	Glutathione S-transferase mRNA	POSITIVE
	MRP mRNA	POSITIVE

10 <sup>1)</sup> Note on the parameter:  
In contrast to the control cells, the lymphocytes were unable to accumulate any doxorubicin. This made determination of the efflux impossible.

15 <sup>2)</sup> Note on the parameter:  
Compared with the positive control cells, no expression of the MDR1 pump gp170 was detectable on the lymphocytes. Quantitative analysis revealed the following:  
Nonspecific antibody binding capacity (ABC): 1523  
20 Specific ABC: 4165

#### d) Assessment

Cancer cells of the carcinoma type with enhanced transcription of the cancer-specific splice variant of  
25 the MUC1 gene were detectable in the patient's blood circulation.

Since analyses of the above angiogenesis factors had negative results, it was not possible to detect any cells capable of neoangiogenesis, the functional interplay of  
30 endothelial and epithelial cells. The circulating cancer cells therefore showed no ability to metastasize; there was not assumed to be any formation of active metastases. The cells circulating in the blood expressed the progesterone receptor. There was no evidence of drug  
35 resistance in the patient.

#### e) Summary and conclusion

Overall, the findings possibly indicated a carcinoma of a hormone-sensitive organ.



**Example 8:**

a) Initial clinical situation

The patient to be investigated had a suspect breast finding (walnut-sized tumour with unremarkable mammography) leading to suspicion of breast carcinoma. In the family there were known to be three cases of breast neoplasms, including two in patients less than 50 years of age, and one case of an ovarian neoplasm. Hence there was a genetic predisposition to tumours. A blood sample was taken.

b) Query

Were there any circulating cancer cells able to form metastases in the blood sample taken?

c) Investigations and results

15	Investigation	Result
	anti-p53	NEGATIVE
	Pan p53	87 pg/ml normal up to 646 marginal up to 786 pathological above 787
	c-erb-B2	2540 HNU/ml normal up to 3385 marginal 3386 - 3845 pathological >3845
20	p53 mutation in tumour cells	NEGATIVE
	p53(exon5) mutation	NEGATIVE
	p53(exon6) mutation	NEGATIVE
	p53(exon7) mutations	NEGATIVE
	p53(exon8) mutations	NEGATIVE
25	erb-B2 after tumour cell isolation	NEGATIVE
	c-myc after tumour cell isolation	NEGATIVE
	CK20 mRNA fraction A	POSITIVE
30	CEA mRNA fraction A	weak positive

002290 152858460

	MUC1 mRNA fraction A	0.86
	bFGF mRNA fraction A	POSITIVE 909 corresponds to 100% (fraction A)
	bFGF-R mRNA fraction A	NEGATIVE
	VEGF mRNA fraction A	POSITIVE 72437 corresponds to 100% (fraction A)
5	VEGF-R1 mRNA fraction A	NEGATIVE
	VEGF-R2 mRNA fraction A	NEGATIVE
	TIMP3 mRNA fraction A	POSITIVE
	MMP2 mRNA fraction A	weak positive
	Progesterone R mRNA	NEGATIVE
10	EGP mRNA fraction A	104097 (corresponds to 100%)
	GAPDH mRNA fraction A	153350963 (corresponds to 100%)
	CK20 mRNA fraction C	NEGATIVE
	CEA mRNA fraction C	NEGATIVE
	MUC1 mRNA fraction C	0.00
15	bFGF mRNA fraction C	0.00
	VEGF mRNA fraction C	1738 (2.4% based on fraction A)
	TIMP3 mRNA fraction C	NEGATIVE
	MMP2 mRNA fraction C	NEGATIVE
	EGP mRNA fraction C	0
20	GAPDH mRNA fraction C	108644 (corresponds to 0.00708% of fraction A)

d) Assessment

Small amounts of cancer cells of the carcinoma type with enhanced transcription of the cancer-specific splice variant of the MUC1 gene were detectable in the patient's blood circulation. Expression of CK20 and CEA was also

detectable. These expression characteristics indicated a breast carcinoma. However, it was not possible to concentrate the circulating cancer cells.

Since the analyses of the above angiogenesis factors had  
5 positive results in some instances (expression of bFGF and VEGF), cells capable of neoangiogenesis, the functional interplay of endothelial and epithelial cells, were detectable. The circulating cancer cells therefore showed signs of an ability to metastasize. This was also  
10 indicated by the expression of the MMP2 gene. The formation of active metastases was therefore very probable. The progesterone receptor was not expressed by the cells in the blood circulation.

e) Summary and conclusion

15 Overall, the findings indicated a spreading carcinoma. The circulating cells originated from the breast.

### GLOSSARY

#### 20 **AFP (alpha-fetoprotein)**

AFP is the main plasma protein in the fetus. There is very little expression of AFP in adults unless a tumour such as a hepatoma or a teratoma is present.

**Ref.:** Gibbs et al.; Biochemistry 26: 1332-1343, 1987.

25

#### **B-Actin**

**Ref.:** Pollard, T.D. and Cooper, J.A.; Ann. Rev. Biochem. 55, 987 ff, 1986.

#### 30 **Albumin (ALB)**

Albumin is used for identifying hepatoma cells circulating in the blood.

**Ref.:** Minghetti et al.; J. Biol. Chem. 261: 6747-6757, 1986.

35

**AR (androgen receptor)**

Synonyms: Dihydrotestosterone receptor, testosterone receptor, TFM

Prostate carcinoma cells are dependent on the growth-stimulating effect of the AR. In prostate carcinomas it has been possible to detect mutations in the androgen receptor, some of which lead to a receptor with constitutive activity.

**Ref.:** Lubahn et al.; Proc. Natl. Acad. Sci. USA 87(11): 9534-9538, 1989.

**BA46 (breast epithelial antigen 46)**

Synonym: human milk fat globule protein

The glycoprotein BA-46 is expressed by breast carcinomas and has been used successfully as the target of experimental radioimmunotherapies.

**Ref.:** Couto et al.; DNA Cell Biol. 15: 281-286, 1996.

**Basic fibroblast growth factor (bFGF)**

Synonym: FGF-2

There is overexpression of bFGF in many types of tumours and it can therefore be regarded as a factor for the ability to metastasize.

**Ref.:** Abraham et al.; EMBO J. 5: 2523-2528, 1986.

**BAX**

The bcl-2 product heterodimerizes in vivo with a conserved homologue, BAX, which expedites programmed cell death.

**Ref.:** Tsujimoto Y. and Croce C.M.; PNAS, 83 (14), 5214-5218, 1986.

**bcl-2**

The bcl-2 gene was discovered in follicular non-Hodgkin lymphomas (B-cell lymphomas). BCL-2 can block apoptosis.

**Ref.:** Tsujimoto Y. and Croce C.M.; PNAS, 83 (14), 5214-

0022290-62853750

5218, 1986.

### **BRCA1**

5 The BRCA1 gene is a tumour suppressor gene. 5-10% of patients with breast cancer have a genetic predisposition, which is frequently associated with a predisposition for ovarian carcinomas too. Mutations in the BRCA1 gene are associated with 45% of breast carcinomas with a genetic component. Mutations in the  
10 BRCA1 gene also relate to ovarian carcinomas.

**Ref.:** Smith T.M., et al.; Genome Res. 6, 1029-1049, 1996.

### **BRCA2**

15 The BRCA2 gene is a tumour suppressor gene. Mutations in this gene are thought to be responsible for a large proportion of hereditary breast tumours which develop early.

**Ref.:** Lancaster J.M., et al.; Nature Genet. 13, 238-240, 1996.

20

### **Calcitonin**

Calcitonin (32 amino acids) is, like calcitonin gene-related peptide (CGRP; 37 amino acids), encoded by the calc-1 gene. Calcitonin can inhibit the growth of a  
25 gastric carcinoma cell line, and the neurohormone CGRP can act as autocrine growth factor for murine carcinoma cell lines.

**Ref.:** Adema and Baas; BBRC 178: 985-992, 1991.

### **CC10 (Clara cell 10 kD protein)**

30 CC10 is expressed only in type 2 alveolar epithelial cells and in Clara cells of the pulmonary epithelium and is involved in the production of epithelial lining fluid.

**Ref.:** Hay J.G. et al, Am. J. Physiol. 268: L565 (1995).

35

002250" 62858460

**CCK (cholecystokinin)**

CCK is a brain and bowel hormone. CCK is additionally expressed by some sarcoma/neuroepithelioma cell lines.

**Ref.:** Friedman, J.M. et al.; PNAS 89: 5819-5823, 1992.

5

**CD44**

Synonyms: Hermes antigen, Pgp-1

The CD44 glycoprotein is a cell adhesion molecule. Certain splice variants of CD44 are involved in the process of tumour metastasis.

10

**Ref.:** Matsumura, Y. and Tarin, D.; The Lancet 340, 1053-1058, 1992.

**CEA (carcinoembryonic antigen)**

15      Synonym: CD66e

CEA is expressed in gastrointestinal and colorectal carcinomas, but also in various solid tumours such as breast carcinomas, in the foetal colon, but not in normal lymphocytes. Because of this expression profile, detection of CEA-positive cells in the blood is used for diagnosing circulating tumour cells. In addition, CEA immunoassays are important diagnostic methods for the observation of cancer patients, especially in cases of colon carcinoma.

20

25      **Ref.:** Zimmermann et al.; Proc. Natl. Acad. Sci. USA 84: 2960-2964, 1987.

**CK20 (cytokeratin 20)**

Malignant cells usually retain the cytokeratin pattern, and this can accordingly be used for localizing the tumour cells back to an epithelium. Since CK20 is not expressed by peripheral blood cells but mainly by cells of the gastrointestinal tract, this cytokeratin is used for detecting tumour cells originating therefrom and circulating in the blood.

30

35

**Ref.:** Moll et al.; Differentiation 63: 75-93, 1993;

09485879.062200

Burchill et al.; British Journal of Cancer 71:278-281, 1995.

### **Cyclin A, B(1), D1, D2, D3, and E**

5 Cyclins and cyclin-dependent kinases (CDK) are essential for control of the cell cycle of eukaryotic cells. Measurement of the cyclins correlates with the cell cycle.

Ref.: Motokura T., et al.; J. Biol. Chem. 1992 Oct 5;  
10 267(28): 20412-5;  
Lees E., et al.; Genes-Dev. 1992 Oct; 6(10): 1874-85.

### **Cyclin G**

15 Cyclin G1 and cyclin G2 are two only recently identified cyclins which play a part in the cell cycle.

Ref.: Horne M.C., et al.; J. Biol. Chem. 1996 Mar 15;  
271(11): 6050-61.

### **DCC**

20 Sequences are frequently deleted from chromosome 18 in colorectal tumours (DCC = deleted in colorectal carcinomas). Expression of the DCC gene is greatly reduced in most colorectal carcinomas. Loss of the 18q region is associated with a poor prognosis. The status of  
25 the DCC gene can be determined by means of microsatellite markers and PCR on formalin-fixed material.

Ref.: Frank C.J., et al.; Cancer Res. 57, (5), 824-827, 1997.

### **DPC4**

30 The name means "deleted in pancreatic carcinoma". About 90% of human pancreatic carcinomas show an allele loss on chromosome 18. A tumour suppressor gene is involved. Changes in the DPC4 gene have also been discovered in  
35 breast and ovarian carcinomas.

Ref.: Hahn S.A., et al.; Science 271, 350-354, 1996.

002230 62958460

## **E-Cadherin**

### **Catenin ( $\alpha$ - and $\beta$ -)**

E-Cadherin is important, in conjunction with associated catenins ( $\alpha$ -catenin;  $\beta$ -catenin), for organogenesis and histogenesis of epithelial tissue and plays a central part in the process of carcinoma metastasis.

**Ref.:** Aberle H., et al.; J. Cell. Biochem. 1996 Jun 15; 61(4): 514-23.

### 10 **EGF (epidermal growth factor)**

Synonyms: HMGF (human milk growth factor); PGF (prostatic growth factor); urogastrone

EGF is involved in embryonic development (ectodermal, mesodermal and endodermal cells) and controls/stimulates the proliferation of epidermal and epithelial cells in vitro. EGF may likewise act as an angiogenic and chemotactic factor.

**Ref.:** Carpenter: EGF; Curr. Opin. Cell. Biol. 5: 261-264, 1993.

20

### **EGF-R (EGF receptor)**

Synonym: SA-7 (species antigen 7)

There is overexpression of EGF-R in some human tumours, and this correlates with the aggressiveness of the tumour; a poor prognosis is indicated by coexpression of EGF-R with either c-erb-B2 or TGF-alpha.

**Ref.:** Ibelgaufte: Dictionary of cytokines, VCH, 1994.

### **EGP (epithelial glycoprotein)**

30 Synonyms: GA733-2; 17-1A antigen; KS1/4

Epithelial glycoprotein can be used as epithelium-specific marker for detecting carcinomas.

**Ref.:** Simon, B. et al.; PNAS 87: 2755-2759, 1990;

Szala, S. et al.; PNAS 87: 3542-3546, 1990.

35

09485879.062200



### **Enteroglucagon**

Synonyms: EG, glucagon 37

Enteroglucagon is a peptide produced by jejunoileal cells.

5 **Ref.:** Bell, G.I. et al.; Nature 304: 368-371, 1983.

### **erb-B**

The erb-B gene codes for the receptor (EGF-R) of epidermal growth factor (EGF). This gene is amplified in  
10 about 50% of advanced human glioblastomas.

**Ref.:** Haley J., et al.; Oncogene Res. 1, 375-396, 1987.

### **erb-B2**

Synonyms: c-erb-B2; avian erythroblastic leukaemia viral  
15 oncogene homologue 2; NGL (neuroblastoma or glioblastoma-derived); neu; tyrosine kinase-type cell surface receptor  
HER2; TKR1

Erb-B2 encodes a tumour antigen, P185, which is serologically related to the epidermal growth factor  
20 receptor (EGF-R). Overexpression converts the gene for a normal growth factor receptor, erb-B2, into an oncogene. Amplification of erb-B2 is observed in adenocarcinomas and in breast and ovarian cancer. Erb-B2 is additionally involved in the development of acute promyelocytic  
25 leukaemia (APL) because the gene is located in band q21.1 of chromosome 17 where the breakpoint of the translocation between chromosome 15 and 17 is also located (t15:17).

**Ref.:** Slamon et al.; Science 244: 707-712, 1989.

30

### **FAP (APC)**

The gene of familial adenomatous polyposis coli, an autosomal dominant disorder, is fap.

**Ref.:** Groden J. et al.; Cell 66: 589-0, 1991.

35

002230 "62853460

**FAS-R; FAS-L (CD95, CD95-L)**

FAS belongs to the group of apoptosis-inducing factors.

**Ref.:** Alderson M.R.; J. Exp. Med. 181, (1), 71-77, 1995;  
Itoh N.; Cell 66, (6), 233-243, 1991.

5

**FGF receptors**

Synonyms: fms-like tyrosine kinase-2; FLT2; FMS-like  
gene; FLG (bFGF-R1); K-SAM, bek (FGF-R2)

Differences in expression and alternative splicing may be  
10 critical in the malignant progression of tumours.

**Ref.:** Yamaguchi et al.; Proc. Natl. Acad. Sci. USA 91:  
484-488, 1994.

**c-fos**

15 The c-fos and c-jun genes play a central part in growth  
regulation.

**Ref.:** Ekstrand A.J., et al.; Exp. Cell. Res. 169. 262-  
266, 1987.

20 **GADD45**

Gadd45 is a growth arrest- and DNA damage-induced gene  
which is regulated by the p53 tumour suppressor gene.

**Ref.:** Constance, C.M. et al.; Mol. Cell. Biol. 1996 Jul;  
16(7): 3878-83

25 Crawford, D.R. et al.; Arch. Biochem. Biophys. 1996 May  
15; 329(2): 137-44.

**GAPDH (glyceraldehyde-3-phosphate dehydrogenase)**

This gene is expressed in all cells. Expression of this  
30 gene correlates with the number of cells and is used for  
quantitative and qualitative determination of cDNA.

**Ref.:** Allen, R.W. et al.; J. Biol. Chem. 262 (2), 649-  
653, 1987.

35

002290"6298460

**Gastrin (GAS)**

Gastrin is produced mainly by mucosal cells of the stomach and the D cells in the pancreas.

Ref.: Boel, E. et al.; PNAS 80: 2866-2869, 1983.

5

**GD-AIF (glioma-derived angiogenesis inhibitory factor)**

GD-AIF is, just like thrombospondin and angiostatin, one of the endogenous negative regulators of angiogenesis. The extent to which the negative regulators decrease during the changeover phase to the angiogenic phenotype of tumour genesis decides whether a primary tumour grows slowly or quickly and whether metastases are formed.

10

Ref.: Folkman J.; Nat. Med. 1 (1995) 27-31.

15

**GIP (gastric inhibitory polypeptide)**

Synonym: glucose-dependent insulintropic polypeptide

This hormone is mainly produced by cells in the upper small intestine.

20

Ref.: Inagaki, N. et al.; Molec. Endocr. 3: 1014-1021, 1989.

**GST-pi (glutathione S-transferase pi)**

GST-pi codes for a detoxifying enzyme and is therefore involved in the development of drug-resistant tumours. An increase in expression has been observed in tumours after chemotherapy, which is associated with an unfavourable prognosis and drug resistance.

25

Ref.: Morrow et al.; Gene 75: 3-11, 1989.

30

**Granzyme**

The main function of the granzymes is to lyse tumour cells and virus-infected cells by apoptotic fragmentation of the DNA.

Ref.: Kummer, J.A. et al.; Kidney Int. 47: 70-77 (1995).

35

002290 6258460

**hCG (human chorionic gonadotropin)**

The  $\beta$  subunit of hCG is used as marker for germ line tumours and choriocarcinomas, and detection of hCG mRNA by RT-PCR is also useful in the diagnosis of metastasizing breast carcinomas and malignant melanomas.  
5      **Ref.:** Doi F. et al; Int. J. Cancer 65 (1996) 454-459.

**HIC-1 (hypermethylated in cancer)**

HIC-1 is regarded as a possible tumour suppressor gene product. Underexpression takes place in tumour cells in which it is hypermethylated.  
10      **Ref.:** Wales M. M., et al.; Nat.Med. 1 (1995) 570-577.

**HSP70**

Heat shock proteins such as HSP70 may play a part in escape mechanisms of tumour cells.  
15      **Ref.:** Kaur J. and Ralhan R.; 63(6): 774-9.

**hTG (human thyroglobulin)**

hTG is a thyroid protein. Four transcripts resulting from alternative splicing have been identified.  
20      **Ref.:** Bertaux et al.; Gene 156: 297-301, 1995.

**ICAM (intercellular adhesion molecules)**

Synonyms: ICAM-1 (CD54, ICAM1-1); ICAM-2 (CD102); ICAM-3  
25      ICAM-1, -2, and -3 are cell surface molecules which act as ligands of leukocyte integrins.

**IGF (insulin-like growth factor)**

Synonyms: MSA (multiplication-stimulating activity); somatomedin; NSILA (non-suppressible insulin-like activity); SF (sulphation factor), SFA, SGF (skeletal growth factor), SMP  
30      IGFs act as mitogenic, autocrine and angiogenic factors.  
35      **Ref.:** Cohick and Clemmons; Annual Review of Physiology 55: 131-153, 1993.

002290 6258460

**IGF-BP3 (insulin-like growth factor binding protein 3)**

Synonyms: IGBP; IBP; BP-53; growth hormone dependent binding protein; binding protein 29

IGF-BP3 acts as growth inhibitor.

- 5 **Ref.:** Lamson; Growth factors 5: 19-28, 1991.

**Integrins**

Integrins are heterodimeric cell surface antigens which are involved in cell-cell and cell-matrix interactions.

- 10 **Ref.:** VIth International Human Leukocyte Differentiation Antigen Workshop and Conference, Kobe (Japan), November 1996.

**Interferon-gamma**

- 15 Synonyms: immune interferon; type 2 interferon; T interferon; antigen-induced interferon; mitogen-induced interferon; ph2-labile interferon

**Ref.:** Gray et al.; Nature 295: 503-508, 1982;

Ibelgaufits: Dictionary of cytokines. VCH 1994.

20

**LOHs**

- Inactivation of tumour suppressor genes is a critical step in the development of tumours. Common mechanisms are both inactivating mutations and the genomic loss of the entire gene or of parts of the gene. The genomic loss of chromosome sections can be envisaged experimentally by the loss of heterozygosity (= LOH). Both alleles of the tumour suppressor gene are found in a patient's normal tissue, whereas only one allele is detectable in the tumour. The two alleles are identified by means of highly polymorphic chromosomal regions located inside or in the vicinity of the tumour suppressor gene (microsatellite repeats), which are amplified by a PCR. These are repeats of short nucleotide sequences (for example CA repeats, CGG repeats), but there are differences in the copy number and thus the product amplified in the PCR varies
- 25
- 30
- 35

00225879 062200

in length.

### **L32**

The ubiquitous expression of L32 makes it suitable as  
5 target gene for quantification.

**Ref.:** Young, J.A. and Trowsdale, J.; Nucleic Acids Res.  
13 (24), 8883-8891, 1985.

### **LRP**

10 Synonyms: protein tyrosine phosphatase; alpha-  
polypeptide; PTPRA; PTPA

Lrp codes for a ubiquitously expressed protein tyrosine  
kinase.

**Ref.:** Jirik et al.; FEBS Lett. 273: 239-242, 1990.

15

### **MAGE1 (melanoma associated antigen-1)**

Synonym: MZ2-E

The MAGE1 gene codes for an antigen on the surface of  
melanoma cells. Whereas MAGE1 can be detected at a high  
20 level in many tumours at the RNA level, the RNA is not  
found in normal tissues with the exception of testis and  
ovary. This gene product is thus extremely suitable as  
marker for circulating tumour cells, in particular  
melanoma cells.

25 **Ref.:** De Plaen et al.; Immunogenetics 40: 360-369, 1994.

### **MAGE3 (melanoma associated antigen-3)**

The MAGE3-encoding gene is transcribed in about 69% of  
melanomas. Since it has hitherto been found only in  
30 tumour tissue and in no normal tissue apart from testis,  
this gene is suitable as marker for circulating melanoma  
cells.

**Ref.:** Gaugler et al.; J. Exp. Med. 179: 921-930, 1994.

35

002250 678860

### **Maspin**

Maspin is a tumour suppressor gene. Defects in this gene are found in particular in breast carcinoma cells.

**Ref.:** Luppi et al.; Annals of Oncol. 7: 619-624, 1996.

5

### **mdm2**

The oncogenic effect of increased MDM2 activity is made evident by inactivation of the p53-induced growth inhibition. Consistent with this, overexpression of mdm2 is found in human tumours.

10

**Ref.:** Zaubermaier et al.; Nucleic Acids Res. 23: 2584-2592, 1995.

### **$\beta$ 2-microglobulin**

$\beta$ 2-microglobulin is expressed on all nucleated vertebrate cells.

**Ref.:** Williams, A.F. and Barclay, A.N.; Annu. Rev. Immunol. 6, 381; 1988.

### **MLH1**

Synonyms: FCC2; COCA2; HNPCC (hereditary nonpolyposis colorectal cancer type 2)

MLH1 gene mutations are responsible for about 30% of a hereditary form of colon carcinoma (hereditary nonpolyposis colon cancer = HNPCC). About 60% of HNPCC cases are, however, caused by mutations in the MSH2 gene on chromosome 2. Two other human genes homologous with MutL have been isolated: pms-1 and pms-2. However, these are less commonly involved than msh2 and mlh1 in the development of tumours.

30

**Ref.:** Bellacosa et al.; Am. J. Med. Genet. 62: 353-364, 1996.

### **MMP (metalloproteinase)**

MMPs are  $Zn^{2+}$ -binding endopeptidases which degrade components of the extracellular matrix. They are involved

35

09445679.062200

in angiogenesis and tumour invasion. There are at least 11 MMPs. Overexpression of metalloproteinases promotes tumour invasion and metastasis. There is enhanced expression of some of these metalloproteinases by tumour cells both on the cell surface and at the mRNA level.

**Ref.:** Freije et al.; J. Biol. Chem. 269: 16766-16773, 1994; Sato et al.; Nature 370: 61-65, 1994.

#### **Motilin (MLN)**

Motilin is a hormone produced by cells of the small intestine.

**Ref.:** Daikh, D.I et al.; DNA 8: 615-621; 1989.

#### **MRP1 (multidrug resistance-associated protein-1)**

The MRP gene codes for a chemotherapeutic efflux pump which is located in the plasma membrane and has similarities with the ATP-binding cassette superfamily of transport systems, which also includes MDR1 and the cystic fibrosis transmembrane conductance regulator.

Overexpression of MDR1 attributable to genomic amplification of the gene was detectable in a drug-resistant cell line of small-cell lung carcinoma.

**Ref.:** Cole et al.; Science 258: 1650-1654, 1992.

#### **MSH2**

This gene plays a part in tumours developed by patients with hereditary nonpolyposis colorectal cancer (HNPCC). MSH2 mutations have been found in 21% of families affected by HNPCC.

**Ref.:** Fishel R., et al.; Science 266, 1403-1405, 1994.

#### **MUC1 (mucin-1)**

Synonyms: PUM, PEM

The MUC1 gene encodes a transmembrane glycoprotein which is formed by tumour cells to protect against cytotoxic immune cells and to promote metastasis. MUC1 is

002290 6293460



synthesized by normal tissues and cells but also by malignant cells and tissues. For example, breast cancer, pancreatic cancer and adenocarcinoma cells show overexpression of the MUC1 protein; moreover, a tumour-specific splice variant is detected in addition to the "normal" variant in some types of cancer.

**Ref.:** Weiss et al.; Int. J. Cancer 66: 55-59, 1996.

### **Muc18**

Muc18 codes for a glycoprotein whose expression is restricted to advanced primary and metastasizing melanomas and to cell lines of the neuroectodermal line. In about 80% of melanomas there is found to be mRNA expression, and the expression correlates with the metastasis status of the cells. The presence of cells expressing this mRNA in the blood is good evidence of circulating tumour cells from an advanced or metastasizing melanoma.

**Ref.:** Lehmann et al.; Proc. Natl. Acad. Sci. USA 86:9891-9895, 1989.

### **myc**

Synonyms: proto-oncogene homologous to myelocytoma virus; c-myc

Amplification of c-myc is found in advanced and in aggressive primary tumours.

**Ref.:** Adams et al.; Proc. Natl. Acad. Sci. 80: 1982-1986, 1983.

### **N-CoR**

N-CoR is a corepressor protein for the retinoic acid  $\beta$  receptor.

**Ref.:** Soderstrom et al.; Mol. Endocrinol. 11:682 (1997).

002250 67853460

### **Neurotensin (NTS)**

Neurotensin is a small neuropeptide localized in the catecholamine-containing neurons.

**Ref.:** Bean, A.J. et al.; Neuroscience 50: 259-268, 1992.

5

### **NF-1**

The NF1 gene is a tumour suppressor gene. The product of the neurofibromatosis-1 gene is neurofibromin or NF1-GAP.

10 NF-1 mutations were found in 10 families with neurofibromatosis (von Recklinghausen's disease).

**Ref.:** Marchuk D.A., et al.; Genomics 11, 931-940, 1991.

### **NF-2**

Synonym: merlin

15 Defects in the NF-2 tumour suppressor gene have been found in type II neurofibromatosis, a hereditary malignant disorder with bilateral tumours of the 8th cranial nerve, neurofibromas, meningiomas, gliomas or schwannomas and in sporadic meningiomas, schwannomas and,  
20 in addition, in melanomas and breast carcinomas.

**Ref.:** Trofatter et al.; Cell 72: 791-800, 1993.

### **nm23**

The nm23-H1 gene is a potential metastasis suppressor.

25 Expression is inversely proportional to the development of lymph node metastases.

**Ref.:** Royds JA., et al.; J. Natl. Cancer Inst. 85, 727-31, 1993.

### **ER (Oestrogen receptor)**

Apart from its function as an important regulator of the growth and differentiation of the mammary gland and the female reproductive tract, the oestrogen receptor is involved in the development of breast carcinomas. The

35 content of oestrogen and progesterone receptor in a tumour is thus an important prognostic marker for the

002230 6253460

success of endocrine therapy. A number of splice variants of the oestrogen receptor have been described and attributed with a function in the development and metastasis of tumours. Thus, a variant of the oestrogen  
5 receptor lacking Exon 5 has been found inter alia in breast cancer cell lines and tumours.

**Ref.:** Greene et al.; Science 231: 1150-1154, 1986.

### **P-glycoprotein (MDR1)**

10 Synonyms: PGY-1; MDR1; GP170 doxorubicin resistance gene; multidrug resistance gene

The mdrl gene codes for a cytostatic efflux pump located in the apical membrane. Treatment of tumours with  
15 chemotherapeutic agents often encounters multidrug resistance to a large number of structurally different therapeutic agents simultaneously. It has been observed experimentally that the mdrl locus is amplified under the influence of chemotherapeutic agents. Increased  
20 expression of this gene has been found in drug-resistant cell lines.

**Ref.:** Gros et al.; Cell 47: 371-380, 1986.

### **p16**

Synonyms: p16(INK4) or CDKN2; MTS1

25 P16 is the name given to cyclin-dependent kinase inhibitors. Deletions of mts1 are characteristic for a large number of tumours. Both deletions and mutations of this gene have been found in melanomas. The frequency of deletions of the CDKN2 gene in tumour cells indicates a  
30 tumour suppressor gene.

**Ref.:** Stone S., et al.; Cancer Res. 55, 2988-2994, 1995.

### **p21**

P21 refers to the human cyclin-dependent kinase  
35 inhibitor.

**Ref.:** Harper J.W., et al.; Cell 75 (4), 805-16, 1993.

0022990 6289460

### **p53**

Mutations in the p53 gene are among the commonest genetic alterations in malignant tumours in humans. In most of these tumours there is found to be loss of one allele of the p53 gene (breast carcinoma (32-64%); ovarian carcinoma (44-66%); gastric carcinoma (>60%); bladder carcinoma (38-58%); pancreatic carcinoma (70%); lung carcinoma (20%); prostate carcinoma (59%); cervical carcinoma (50%)). The mutations are distributed along the entire length of the protein, with clustering in Exons 5 to 8 and some other exons also frequently being affected (codons 175, 245, 248, 249, 273). The frequency of these hotspot mutations varies with the organ of origin of the tumour. Mutations in codon 175 are found, for example, in 6% of breast carcinomas, 14% of colorectal tumours and 4% of ovarian carcinomas. They are almost exclusively point mutations occurring over a wide region of the gene.

**Ref.:** Levine A.J.; Nature 351, 453, 1991.

### **PDGF (platelet-derived growth factor)**

Synonyms: PDGF; GDGF; GDGF-1; GDGF-2; GSM; MDF; MDGF; ODGF; T47D factor

PDGF is a local autocrine and paracrine growth factor with chemotactic activity, a potent vasoconstrictor and angiogenesis factor.

**Ref.:** Westermark und Sorg: Biology of platelet-derived growth factor. Karger, Basel 1993.

### **Peptide YY**

Synonym: PYY

There is endocrine synthesis of PYY by cells of the small intestine, the colon and the pancreas.

**Ref.:** Hort, Y. et al.; Genomics 26: 77-83, 1995.

### **Perforin-1**

Synonyms: cytolysin; C9-related protein; pore-forming

002290 6283460

protein; PFP

Perforin-1 belongs to a class of cytolytic proteins which permeabilize the membranes of target cells.

**Ref.:** Ojcius und Young; TIBS 16: 225-229, 1991.

5

**PR (progesterone receptor)**

Synonym: PGR

10 A large content of progesterone receptor in a breast carcinoma is a prognostic marker for the response to endocrine therapy and prolonged survival. Consistent with this, progesterone has a protective effect in relation to breast cancer. Analysis of the progesterone receptor in breast carcinomas is of particular interest because the presence of the oestrogen receptor can also be determined indirectly.

15

**Ref.:** Misrahi et al.; Biochem. Biophys. Res. Commun. 143: 740-748, 1987.

**PSM (prostate-specific membrane antigen)**

20 Normal and neoplastic prostate cells express PSM.

**Ref.:** Israeli et al.; Cancer Res. 53: 227-230, 1993.

**PSA (prostate-specific antigen)**

Synonym: APS

25 The PSA level is measured in radioimmunoassays for the diagnosis and monitoring of prostate carcinomas.

**Ref.:** Lundwall et al.; FEBS Lett. 214: 317-322, 1987.

**Ras**

30 The cellular genes of the ras gene family are named after the corresponding retroviral oncogenes. Their names are: c-Harvey-ras (c-H-ras), c-Kirsten-ras (c-K-ras) and N-ras (discovered in neuroblastomas).

35 Mutations in codons 12, 13 and 61 are found both in solid and in haemopoietic tumours. RAS mutations can frequently be detected in pancreatic, thyroid and colorectal

002290 6258460

carcinomas. Most of the mutations in colorectal tumours are G-A transitions, which permits conclusions to be drawn about alkylating agents.

**Ref.:** Bos J.L.; Cancer Res., 49, 4682-9, 1989.

5

#### **RB (retinoblastoma)**

Loss or inactivation of the RB gene is crucial for the development of retinoblastomas. Loss of the function of the gene in both alleles leads to development of the tumour. Microsatellites and RFLP can be used for DNA diagnosis in cases of familial retinoblastoma.

10

**Ref.:** Friend S.H., et al.; PNAS 84, (24) 9059-63, 1987.

#### **RET**

The RET oncogene is frequently rearranged and recombined with another gene in papillary thyroid carcinomas. Germline mutations of the RET oncogene have been detected in a high percentage of patients with multiple endocrine neoplasms of the MEN 2A type and of patients with familial thyroid carcinoma (FMTC).

20

**Ref.:** Viglietto G et al.; Oncogene 1995 Sep 21, 11(6): 1207-10.

#### **SCCA-1 (squamous cell carcinoma antigen-1)**

The protein SCCA-1 was isolated from a metastatic cervical squamous cell carcinoma. SCCA-1 is used as marker for squamous epithelial carcinomas in particular of the cervix, of the throat and neck, of the lung and of the oesophagus, the amount of the antigen in the blood correlating with the progression.

30

**Ref.:** Schneider et al.; Proc. Natl. Acad. Sci. U.S.A. 92: 3147-3151, 1995.

#### **P-, L- and E-Selectin**

Selectins are transmembrane glycoproteins which are expressed on various cell types such as platelets (P-

35

002290 6285450

selectin), leukocytes (L-selectin) and endothelial cells (E- and P-selectin). The pattern of expression of the selectins and their ligands on cells provides information on the recirculation behaviour of the relevant cell.

5 **Ref.:** Springer, T.A. et al.; Cell 76: 301-314, 1994.

### **SF (scatter factor)**

Synonym: hepatocyte growth factor (HGF)

10 SF is mainly expressed by mesenchymal cells, stroma and fibroblasts and is a potent angiogenesis and motility factor which, as a tumour cell autocrine factor, can enhance their invasiveness as well as tumorigenesis.

**Ref.:** Nakamura et al.; Nature 342: 440-443, 1989;

Bellusci et al.; Oncogene 9: 1091-1099, 1994.

15

### **c-met SF receptor**

Synonym: met proto-oncogene

The c-met proto-oncogene plays an important part in the development of tumours.

20 **Ref.:** Park et al.; Proc. Natl. Acad. Sci. USA 84: 6379-6383, 1987.

### **STAT5 (signal transduction and activator of transcription 5)**

25 STATs are a family of proteins which both perform a signal transduction function and are transcription activators.

**Ref.:** Darnell; PNAS 93: 6221-6224, 1996.

### **Surfactant proteins**

Synonyms: surfactant protein (SP)-A, -B, -C; -D

30 Surfactant protein A is, for example, expressed only by type II alveolar epithelial cells and Clara cells in lung tissue and SP-C is expressed exclusively by type II alveolar cells. There are several surfactant proteins (A1 and A2, B, C and D) whose expression (for example mRNA)

35

002230 6258460

has been described in metastatic, micrometastatic, pulmonary and extrapulmonary adenocarcinomas, non-small-cell lung carcinomas and breast carcinomas.

**Ref.:** Betz et al.; Cancer Res. 55: 4283-4286, 1995.

5

### **Telomerase**

Telomerases define the ends of chromosomes.

**Ref.:** Morin G.B., et al.; Nature 353, 454-456, 1991.

Blackburn E.H.; Nature 350, 569-573, 1991.

10

### **TGF-alpha (transforming growth factor alpha)**

Synonyms: MDGF-2 (milk-derived growth factor 2); TGF-1; TCGF (transformed cell growth factor)

TGF-alpha is expressed by a large number of carcinomas and transformed (by viral or cellular oncogenes) cell lines. It may act as autocrine growth factor in ovarian carcinomas or as haematopoietic growth factor and may be involved in the vascularization of tumour tissue.

**Ref.:** Derynck; Advances in Cancer Research 58: 27-52, 1992.

20

### **TIMP (tissue inhibitors of metalloproteinases)**

The TIMPs belong to a family of inhibitors of the activity of metalloproteinases and thus counteract tissue disintegration and help determine the invasion and metastasis of carcinoma cells into the tissue.

**Ref.:** Apte et al.; Genomics 19: 86-90, 1994.

25

### **TNF-alpha (tumour necrosis factor alpha)**

Synonyms: cachectin; monocyte/macrophage-derived TNF; cytotoxin (CTX); endogenous pyrogen; TNF- $\alpha$

TNF-alpha exerts a direct cytotoxic and apoptotic effect on tumour cells.

**Ref.:** Wang et al.; Science 228: 149-154, 1985.

35

002230 5759460



### **TNF-R1 p55**

Synonyms: CD120a; cytotoxic TNF-R

TNF-R1 stands for human tumour necrosis factor receptor 1 and mainly mediates cytotoxicity and apoptosis.

5 **Ref.:** Loetscher H., et al.; Cell 61, 351-59, 1990.

### **TNF-R2 p75**

Synonym: C120b; TNFBR

TNF-R2 mainly mediates T-cell activation.

10 **Ref.:** Beltinger C.P.; Genomics 35, 94-100, 1996.

### **Topoisomerase II**

Synonyms: TOPO; TOP2A; topoisomerase alpha

15 DNA topoisomerases are ATP-dependent enzymes which control the topological status of DNA. Drug resistance may be found in tumours in which topoisomerase activity is reduced, such as, for example, by reduced expression. In addition, a mutation of the topoisomerase gene has been isolated from drug-resistant cell lines and has the  
20 effect that the enzyme is no longer inhibited by the chemotherapeutic agent.

**Ref.:** Hinds et al.; Cancer Research 51: 4729-4731, 1991.

### **Translocations and rearrangements**

25

#### **B- and T-cell receptor rearrangements**

There is rearrangement of the immunoglobulin (Ig) genes during B-cell differentiation and of the T-cell receptor (TCR) during T-cell maturation. If a multiplication of a  
30 T-cell clone is found in the blood of a patient, it can be identified against the polyclonal background of all the remaining T lymphocytes.

**Ref.:** Trainor et al.; Blood, 78, 192-196, 1991.

Lehman et al.; Am. J. Clin. Pathol. 103, 171-176, 1995.

35

**Translocation (14;18)**

This translocation is the commonest in human lymphomas. It is found in more than 80% of follicular lymphomas, in about 20% of diffuse large-cell lymphomas and in about 50% of adult undifferentiated lymphomas.

**Ref.:** Barker et al.; Blood, 83, 1079-1085, 1994.

**Translocation (9;22)**

Synonyms: Philadelphia chromosome, BCR/ABL

The Philadelphia chromosome is brought about by a reciprocal translocation between chromosomes 9 and 22 which is found in the tumour cells of about 90% of patients with chronic myeloid leukaemia (CML). A small incidence of this rearrangement is also found in acute lymphatic leukaemias. Only 3 different possible fusion transcripts result, and they can be used to detect a CML or minimal residual disease.

**Ref.:** Maurer et al.; The Lancet, 337, 1055-1058, 1991.

**Translocations (2;13) and (1;13)**

A specific cytogenetic abnormality found in 68% of alveolar rhabdomyosarcomas is translocation (2;13) in which the genes of transcription factors PAX3 (chromosome 2) and FKHR (chromosome 13) are involved.

14% of alveolar rhabdomyosarcomas have translocation (1;13) where the PAX7 gene on chromosome 1 is involved instead of the PAX3 gene on chromosome 2.

**Ref.:** Sreekantaiah et al.; American J. Pathol., 144: 1121-1134, 1194.

**Translocation (x;18)**

This translocation is found in 91% of all synovial sarcomas. The SSX gene of chromosome X and the SYT gene of chromosome 18 are involved, leading to a fusion transcript which presumably occupies a key position in the development of tumours.

**Ref.:** Clark et al.; Nature Genetics, 7, 502-508, 1994.

**Translocation (12;16)**

This translocation occurs in 77% of all myxoid  
5 liposarcomas and involves the genes of the transcription  
factor CHOP (chromosome 12) and the FUS gene (chromosome  
16) whose function is still unknown.

**Ref.:** Rabbits et al.; Nature Genetics, 4, 175-180, 1993.

10 **Translocation (11;22)**

This translocation is found in 86% of all Ewing's  
sarcomas and results in the formation of a fusion  
transcript consisting of the EWS gene (chromosome 22) and  
the FLI gene (chromosome 11).

15 **Ref.:** West et al.; J. Clin. Oncol., 15, 583-588, 1997.

**$\alpha$ - and  $\beta$ -tubulin**

Tubulins are the monomer components of the microtubules  
of the cytoskeleton.

20 **Ref.:** J. Biol. Chem. 272:2534 (1997).

**Tyrosinase**

Tyrosinase is a key enzyme of melanin synthesis and is  
expressed only in melanocytes and melanoma cells.

25 Detection of tyrosinase-expressing cells in the blood  
therefore indicates the presence of circulating melanoma  
cells in the blood.

**Ref.:** Giebel et al.; Genomics 9. 435-445, 1991.

30 **UPA (urokinase-type plasminogen activator) and  
PAI-1 (plasminogen activator inhibitor 1)**

UPA is a proteolytic enzyme whose expression correlates  
with increased invasiveness, tumour-associated  
angiogenesis and metastasis. Its activity is regulated by  
35 an inhibitor (PAI-1). Investigations inter alia on  
primary breast carcinoma and gastric carcinoma have shown

002250 6285460

that high levels of UPA are associated with a poor prognosis. This is consistent with the lack of expression of PAI-1 in aggressive tumour cells. The balance between UPA and PAI-1 thus forms a prognostic parameter for the metastasis and angiogenesis ability of a tumour.

**Ref.:** Ito et al.; Virchows Arch. 427:487-497, 1996.

**VEGF (vascular endothelial growth factor)**

Synonyms: VPF; vascular permeability factor; vasculotropin; CD(glioma-derived)-VEGF

VEGF may, as a consequence of alternative splicing of the mRNA, occur in four forms, namely VEGF121 and VEGF165, and VEGF189 and VEGF206. VEGF appears to play an important part in the control of blood vessel formation and permeability and moreover to be a main regulator of tumour angiogenesis.

**Ref.:** Leung et al.; Science 246: 1306-1309, 1989.

Tischer et al.; J. Biol. Chem. 266: 11947-11954, 1991.

**VEGF-R1 (VEGF receptor 1)**

Synonyms: FMS-like tyrosine kinase-1; flt1 vascular endothelial growth factor/vascular permeability factor receptor; oncogene flt

An increased expression of VEGF-R1 in carcinomas has frequently been described.

**Ref.:** Shibuya et al.; Oncogene 5: 519-524, 1990.

**VEGF-R2 (VEGF receptor 2)**

Synonyms: KDR; tyrosine kinase growth factor receptor; FLK-1 receptor for vascular endothelial growth factor; FLK1; kinase insert domain receptor

The up-regulation of VEGF mRNA in tumour cells and of the mRNA of its receptors in the tumour vasculature correlates with an increased aggressiveness of the tumour. VEGF-R2 is also transcribed in melanoma and ovarian tumour cells.

**Ref.:** Terman et al.; Oncogene 6: 1677-1683, 1991;  
Boocock et al.; J. Natl. Cancer Inst. 87: 506-516, 1995.

### **VHL (Von Hippel-Lindau syndrome)**

5 The VHL gene product is a tumour suppressor protein which  
leads in the case of genetic mutations to renal  
carcinomas, haemangiomas of the cerebellum and retina,  
phaeochromocytomas and ependymomas. It has likewise been  
shown to be involved in the development of spontaneous  
10 tumours.

**Ref.:** Latif et al.; Science 260: 1317-1320, 1993.

### **Viral oncogenes**

Of particular importance for viral oncogenesis are  
15 hepatitis B and C viruses, possibly also SV40, in  
relation to hepatocellular carcinomas, the HTLV-1 virus  
in connection with T-cell lymphomas, the Epstein-Barr  
virus (EBV) in connection with Burkitt's lymphomas,  
nasopharyngeal carcinomas and Hodgkin's disease and human  
20 papillomaviruses of types 16 and 18 in connection with  
carcinomas in the urethrogenital region, in particular of  
the cervix.

In addition, herpesviruses of types 4 and 6 and the HI  
virus have been suggested to be connected with the  
25 development of tumours.

**Ref.:** Mueller M.; Environ. Health Perspect. 103 (1995)  
Suppl.8, 259-261.

### *Hepatocellular carcinomas*

30 **Ref.:** De-Vita S. et al.; Blood 86 (1995) 1887-1892.  
Koike K.; Intervirology 38 (1995) 134-142.  
Casola S. et al.; Acta Genet. Med. Gemellol Roma 45  
(1996) 221-225.  
E Hara et al.; Dev.Genet. 18 (1996) 161-172.

35

*Urethrogenital carcinomas (cervical carcinomas, vulval*

002280 6255460

carcinomas, prostate cancer, anal cancer, bladder cancer)

**Ref.:** Beyer-Finkler E. et al.; Intervirology 38 (1995) 173-180.

Moyet-Lalle C. et al.; Int. J. Cancer 64 (1995) 124-129.

5

*Lymphomas* (non-Hodgkin lymphomas, Burkitt's lymphomas, T-cell lymphomas, B-cell lymphomas)

**Ref.:** Lee J.H. et al.; J. Korean Med. Sci. 10 (1995) 399-405;

10 Tomita Y. et al.; Leuk. Lymphoma 19 (1995) 129-134.

Wang C.Y. et al.; Mayo Clin. Proc. 70 (1995) 665-672;

Maroushek S.R. et al.; Microb. Pathog. 19 (1995) 317-333.

*Lung carcinomas*

15 **Ref.:** Hogg J.C., Hegele R.G.; Semin Resp. Infect. 10 (1995) 244-253.

**WT1**

20 Wilms tumours are kidney tumours of children. It is very probably a tumour suppressor gene.

**Ref.:** Bonetta L., et al.; Cytogenet. Cell Genet. 51, 1989.

Gessler M., et al.; Genomics 12, 807-813, 1992.

002230 6255450

09/485879  
34

6)

09/485879

93

416 Rec'd PCT/PTO 16 FEB 2000

PCT/EP98/05360

P A T E N T   C L A I M S

1. Method for the multiple characterization of disseminated and micrometastasized cancer cells on the basis of DNA and/or RNA, wherein cells obtained from body fluid from an individual are investigated for at least one cancer-specific gene on the basis of mRNA; and  
cancer cells removed from body fluid from an individual are investigated for at least one cancer-specific gene on the basis of DNA and/or mRNA.
2. Method according to Claim 1, characterized in that expression analyses on the basis of mRNA are carried out on those cancer-specific genes which are essentially not expressed in non-cancer cells in the body fluid investigated.
3. Method according to Claim 2, characterized in that mRNA of the CEA, CK20, MUC1, tyrosinase and/or MAGE3 genes is investigated.
4. Method according to Claim 1, characterized in that genomic DNA of the p53, erb-B2, c-myc, K-ras, RB, APC and/or DCC genes is investigated.
5. Method according to any of the preceding claims, characterized in that genomic DNA is investigated for mutations, amplifications, LOHs, translocations and/or polymorphisms of oncogenes and/or mutated tumour suppressor genes.
6. Method according to any of the preceding claims, characterized in that the cells and/or the cancer cells are additionally investigated for at least one cancer-associated gene.

09485879-062200

7. Method according to Claim 6, characterized in that investigation is for tissue-specific genes, metastasis-associated genes, steroid hormone receptor genes, drug resistance genes and/or genes which correlate with immunomodulation, cell proliferation and/or apoptosis.
8. Method according to Claim 7, characterized in that investigation is for metastasis-associated genes which code for angiogenesis factors, motility factors, growth factors, matrix degradation factors such as proteinases and their inhibitors, and/or adhesion factors such as adherins.
9. Method according to any of Claims 6 to 8, characterized in that mRNA is investigated.
10. Method according to Claim 9, characterized in that mRNA of the bFGF, bFGF-R, VEGF, VEGF-R1, VEGF-R2, MMP2 and/or TIMP3 genes is investigated.
11. Method according to any of the preceding claims, characterized in that cancer cells are removed from the body fluid or from cell-containing fractions thereof by immunoadsorption, microfiltration or density gradient centrifugation.
12. Method according to Claim 11, characterized in that single cancer cells are removed and are also investigated singly.
13. Method according to any of the preceding claims, characterized in that an investigation established with cancer cells is also carried out with non-cancer cells from the same individual for comparison.
14. Use of the method according to any of Claims 1 to 13 for the in vitro diagnosis of cancer.

002290" 6/25/8460



15. Use of disseminated and micrometastasized cancer cells characterized by the method according to any of Claims 1 to 13 for testing active substances for an antineoplastic effect.
16. Means for carrying out the method according to any of Claims 1 to 13, comprising suitable primers, probes and/or positive/negative controls and, where appropriate, other means usual for the characterization of DNA and/or RNA.
17. Means according to Claim 16 in the form of a combination of test kits and/or diagnostic kits.

002290 16255460

**ABSTRACT**

The present invention relates to a method for the characterization of disseminated and micrometastasized cancer cells on the basis of DNA and/or RNA, wherein cells obtained from body fluid from an individual are investigated on the basis of mRNA for at least one cancer-specific gene; and/or cancer cells removed from the body fluid of an individual are investigated on the basis of DNA and/or mRNA for at least one cancer-specific gene, and the same investigation is carried out with non-cancer cells from the same individual for comparison. In particular, the cells and the cancer cells are additionally investigated for at least one cancer-associated gene, and the same investigation is carried out on non-cancer cells from the same individual for comparison. The cancer-specific genes include oncogenes, mutated tumour suppressor genes and genes which are essentially not expressed in non-cancer cells in the body fluid investigated. The cancer-associated genes are, for example, tissue-specific, correlate with the ability of circulating cancer cells to metastasize, code for steroid hormone receptors, comprise drug resistance genes and/or correlate with immunomodulation, cell proliferation or apoptosis. The present invention in particular relates to the use of the method for the in vitro diagnosis of cancer. It also relates to the use of disseminated and micrometastasized cancer cells characterized according to the invention for testing active substances for an antineoplastic effect and to means for carrying out the method.

Wo/L

09485879 062200

## DECLARATION AND POWER OF ATTORNEY

As the below-named inventors, we declare that:

Our residences, post office addresses, and citizenships are as stated below under our names.

We believe we are the original, first, and joint inventors of the invention entitled "METHOD FOR THE CHARACTERIZATION OF DISSEMINATED MICROMETASTASIZED CANCER CELLS," which is described and claimed in the specification and claims of Patent Application No. 09/485,879, which we filed in the United States Patent and Trademark Office on February 16, 2000 and for which a patent is sought; which application claims priority from International Application No. PCT/EP98/05360, filed August 24, 1998; which application claims priority from German Application No. 197 36 691.0, filed August 22, 1997.

We have reviewed and understand the contents of the above-entitled specification, including the claims, as amended by any amendment specifically referred to herein (if any).

We acknowledge our duty to disclose information of which we are aware which is material to the patentability and examination of this application in accordance with 37 C.F.R. § 1.56(a).

We hereby appoint RICHARD W. SEED, Reg. No. 16,557; ROBERT J. BAYNHAM, Reg. No. 22,846; GEORGE C. RONDEAU, JR., Reg. No. 28,893; DAVID H. DEITS, Reg. No. 28,066; WILLIAM O. FERRON, JR., Reg. No. 30,633; DAVID J. MAKI, Reg. No. 31,392; RICHARD G. SHARKEY, Reg. No. 32,629; DAVID V. CARLSON, Reg. No. 31,153; KARL R. HERMANN, Reg. No. 33,507; DAVID D. MCMASTERS, Reg. No. 33,963; MICHAEL J. DONOHUE, Reg. No. 35,859; JANE E. R. POTTER, Reg. No. 33,332; ROBERT IANNUCCI, Reg. No. 33,514; LORRAINE LINFORD, Reg. No. 35,939; DAVID W. PARKER, Reg. No. 37,414; ELLEN M. BIERMAN, Reg. No. 38,079; BRIAN G. BODINE, Reg. No. 40,520; ANN T. KADLECEK, Reg. No. 39,244; E. RUSSELL TARLETON, Reg. No. 31,800; KEVIN S. COSTANZA, Reg. No. 37,801; THOMAS E. LOOP, Reg. No. 42,810; STEPHEN J. ROSENMAN, Reg. No. 43,058; BRIAN L. JOHNSON, Reg. No. 40,033; SUSAN D. BETCHER, Reg. No. 43,498; WILLIAM T. CHRISTIANSEN, Reg. No. 44,614; GARY M. MYLES, Reg. No. 46,209; and ERIC J. GASH, Reg. No. 46,274; comprising the firm of Seed Intellectual Property Law Group PLLC, 701 Fifth Avenue, Suite 6300, Seattle, Washington 98104-7092; as our attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Please direct all correspondence to **Richard G. Sharkey** at Seed Intellectual Property Law Group PLLC, 701 Fifth Avenue, Suite 6300, Seattle, Washington 98104-7092, telephone calls to (206) 622-4900 and telecopies to (206) 682-6031.

We further declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

002250 6253450

1-00 h King  
GIESING, Michael

Date

June 6, 2000

Residence

:

City of Recklinghausen  
Country of Germany

DEX

Citizenship

:

Germany

P.O. Address

:

Berghauser Str. 295  
D-45659 Recklinghausen  
GERMANY

002290 62858460


*Frank Austrup*

AUSTRUP, Frank

Date 14.6.00

Residence : City of Recklinghausen *DEX*  
Country of Germany  
Citizenship : Germany  
P.O. Address : Forellstr. 25b  
D-45663 Recklinghausen  
GERMANY

002250"62853460

  
DRIESEL, Gerhard

Date 14.6.00

Residence : City of Recklinghausen  
Country of Germany **DEX**

Citizenship : Germany

P.O. Address : Senheimer Str. 2  
D-45663 Recklinghausen  
GERMANY

002290 67658460

H Claudine Eder

EDER, Claudine

Date 6/15/2000

Residence : City of Recklinghausen DEX  
Country of Germany

Citizenship : Germany

P.O. Address : Norderneystr. 38  
D-45665 Recklinghausen  
GERMANY

002290"6258460



002250 62958450

5/15/2000  
FEIFEL, Nico

Date 6/15/2000

Residence : City of Recklinghausen, DEX  
Country of Germany  
Citizenship : Germany  
P.O. Address : Westerholter Weg 43  
D-45657 Recklinghausen  
GERMANY

Be. Böckmann

HOLEWA, Beatrix

Date 15.6.2000

Residence : City of Recklinghausen DE  
Country of Germany

Citizenship : Germany

P.O. Address : Roonstr. 16  
D-45657 Recklinghausen  
GERMANY

002290 67858460

---

SUCHY, Bernhard

Date 14.6.2000

Residence : City of Recklinghausen  
Country of Germany

Citizenship : Germany

P.O. Address : Alte Grenzstr. 89  
D-45663 Recklinghausen  
GERMANY

Table 1. Demographic characteristics of the study population	
Age (years)	65.5 ± 1.2
Gender (male/female)	10/10
Education (years)	12.5 ± 0.5
Marital status (married/divorced/widowed)	10/0/0
Occupation (retired/working)	10/0
Income (USD/month)	1,200 ± 100
Smoking status (smoker/non-smoker)	5/5
Alcohol consumption (yes/no)	2/8
Comorbidities (hypertension/diabetes/cholesterol)	8/5/3
Medication (antidepressant/antipsychotic)	10/0
Duration of illness (years)	15.5 ± 2.5
Previous hospitalizations (yes/no)	8/2
Family history of mental illness (yes/no)	3/7
Current living situation (alone/with family)	5/5
Social support (strong/weak)	6/4
Stress levels (high/low)	7/3
Life satisfaction (satisfied/dissatisfied)	4/6
Overall health (good/poor)	6/4
Quality of life (high/low)	5/5
Adherence to treatment (yes/no)	10/0
Side effects (yes/no)	2/8
Relapse rate (yes/no)	3/7
Recovery status (recovered/not recovered)	6/4
Long-term prognosis (good/poor)	5/5
Overall outcome (positive/negative)	6/4

